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ABSTRACT
This dissertation examines an individual’s perceived health status, and health
values, as influences on self-initiated health action, specifically the pursuit of Direct-toconsumer (DTC) genome testing. Motivation for this independent health action may also
have implications for other individual health behaviors, including the potential for
positive changes that are lasting rather than temporary. Health Capability, the conceptual
framework, supports individual health values and goals, ability to access valued
healthcare services and includes measures of health status. However, Health Capability
lacks an operationalized mapping of its major concepts. This dissertation proposes and
evaluates an original concept mapping and relationships.
An overview of this dissertation and components is presented in Chapter one.
Chapter two addresses the genomics and healthcare landscape related to independent
individual pursuit of Direct-to-consumer (DTC) genome testing. The Health Capability
framework is initially presented in this chapter, together with the research hypotheses,
targeted literature review of key concepts and the proposed concept mapping with
relationships. Chapter three describes the Health Capability conceptual framework, its
adaptation and extension for the dissertation and its potential for use in health promotion
and prevention research. A systematic review of the literature on perceived health status
is discussed in chapter four, as well as a targeted review of approaches to concept
measurement and most commonly used instruments.
Chapter Five presents the dissertation study. This research involves 1455 selfinitiated Direct-to-consumer (DTC) genome testing users who represent a naturally
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occurring phenomenon and provide a unique population to study the impact of an
individual’s subjective perceived health status, personal health values and health goals.
Participants completed surveys as part of the Impact of Personal Genomics (PGen) study.
These participants were classified into four mutually exclusive health status groups based
on individual perception of health and a healthcare system perspective of health status
(existence of a medical diagnosis). These groups were analyzed for the following: 1)
discrepancies in health status, 2) differences in reasons for genome testing, perceived risk
and health values, and 3) potential relationships among variables. Results confirmed
discrepancies between individual and biomedical health status. One group may represent
the “worried well”. Interest in health information was high (98–99%) across all groups,
as was health value of genome test results. Two items distinguished all groups (interest
in pharmacogenomics information and learning risk for other diseases (p < .001). When
groups differed, perceived rather than biomedical health status was often involved, yet
both factors demonstrated influences (variable dependent). Risk perception was
moderately correlated (.301) with health status group, yet clearly does not equate with
perceived health. Persons with medical diagnoses and self-rated not good health scored
highest for items relating to immediate personal health and for family. Study findings are
consistent with individual perceived health status and health values as significant factors
influencing self-initiated health action (DTC genome testing).
Chapter six further interprets research results as they relate to the hypotheses and
to future research plans. Implications of the study results for revision and extension of
the Health Capability concept mapping and framework are also discussed. These
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include: 1) supporting health status and values as principle concepts; 2) supporting
addition of a measure of individual (subjective) perceived health status; 3) representing
resources outside the healthcare system; and, 4) exploring the possibility of a personal
need or value, as a “trigger” to action. These are areas of planned further research
relevant to personalized healthcare, effective clinical practice, a collaborative healthcare
model and meaningful policy development.
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CHAPTER I
INTRODUCTION & PURPOSE OF THE RESEARCH

Background
An estimated one million persons have self-initiated Direct-to-Consumer (DTC)
genome testing touted for its abilities to identify potential health risks and ancestral
heritage (Genetics & Public Policy Center, 2011; Wojcicki, 2013). Users of this testing
span adults of all ages, with health status varying from having medical diagnoses to
healthy persons. Why do consumers want and pursue this testing despite cautions about
its limitations and the potential harms if results are misinterpreted (American College of
Medical Genetics and Genomics, 2013; American College of Medical Genetics and
Genomics (ACMG), 2012; Clarke, 2013; Hesse, Arora, & Khoury, 2012)? DTC studies
to date of individuals’ motivations have limitations and leave many questions
unanswered (Bloss, Darst, Topol, & Schork, 2011; Facio et al., 2011; Goldsmith,
Jackson, O'Connor, & Skirton, 2012; Gollust et al., 2011; D. J. Kaufman, Bollinger,
Dvoskin, & Scott, 2012). Akin to studies of mortality and morbidity where self-rated
health status was a predictor of health outcomes and reflected actual individual health
(Idler & Benyamini, 1997; Miilunpalo, Vuori, Oja, Pasanen, & Urponen, 1997; Okosun,
Choi, Matamoros, & Dever, 2001), does perceived health status as well as health values
influence individual health needs, goals and motivations on a grander scale (and
throughout the lifespan), regardless of health status or values as determined by healthcare
system standards? If so, this could and should change the face of healthcare.
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From another perspective of this question, consider persons who present to their
healthcare provider with health concerns yet have no diagnosable condition. Are they the
“worried well” (Garfield, 2006), are they cases illustrating discrepancies between health
status as perceived by the individual versus healthcare system assessment criteria
(Kivinen, Halonen, Eronen, & Nissinen, 1998; Okosun et al., 2001), and/or are they
proactive prevention-oriented persons whose needs are not being met in the context of a
disease-oriented biomedical model (Juengst, Settersten Jr, Fishman, & McGowan, 2012;
Personalized Medicine Coalition, 2014)? Are these various groups of persons also
included among DTC genome testing users, hoping to get some answers or information
important to their health functioning? The purpose of the dissertation study is to examine
individual perceived health status (in contrast to health status based on healthcare system
criteria) and individual health values as factors that distinguish and influence (motivate)
individual health needs, goals and actions in persons who independently pursue DTC
genome testing.

Overview and Integration of Chapters, Content and Study
The background, current status, challenges and implications of genomic testing
(including the DTC aspect) for individuals and the healthcare system are presented in
Chapter II. My unique research study (Chapter V) required exploration of a healthcare
model that embodies study concepts and philosophy, bridges the gap between the
traditional biomedical model and respect for individual health values and goals, allows
for independent individual choices and actions (e.g., DTC genome testing), and supports
examination of subjective individual health influences and new strategies for effective
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healthcare services and health promotion. The Health Capability conceptual framework
(Ruger, 2010) fits these criteria and is described in Chapter III, which also presents an
early version of the proposed conceptual process model (since this chapter represents an
article submitted for journal publication in the Fall of 2013). The current, detailed
concept mapping proposal for operationalizing Health Capability, a need recognized by
its author (Ruger, 2010), includes designation of relationships, corresponding hypotheses
and concepts covered in literature review, and is explained in Chapter II. A systematic
review of the literature on perceived health status is described and discussed in Chapter
IV, together with concept measurement approaches and instruments, unifying the Health
Capability model (i.e., author’s suggested consideration of the SF-36 instrument), the
research study (i.e., survey question used to capture this concept) and future potential
research and practice applications. The dissertation research study (Chapter V) examines
health status from the unique perspective of combining an individual’s perceived health
status (dichotomized) with a biomedical assignment of health status (presence/absence of
diagnosis/es), thus creating mutually exclusive health status groups for analysis of
differences related to subjective health factors (i.e., individual health values,
reasons/motivations for testing, perception of health risk). The study population is 1,455
self-initiated DTC genome testing users who completed surveys as part of the large scale
NIH funded Personalized Genomics (PGen) study (R. Green & Roberts, 2012b). This
sample represents a rare, naturally occurring virgin sample of persons who pursued
broad-based health-related genome testing without a healthcare practitioners’ order or as
part of an approved research study.
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Results of this dissertation research have current and future substantive relevance
to genome testing, healthcare models and health-related applications across individuals,
populations, ages, ethnicities, and all clinical practices, as discussed in Chapter VI.
Beyond the genomics context, this study offers real potential to gain new, previously
unrecognized or misinterpreted, insights into subjective human factors and health values
that may contribute to, or even trump, biomedical factors as influences on individual
health-related needs, actions, receptivity to information and interventions, and
implementation as well as endurance of health-related behaviors. These factors are
important to effective and efficient allocation, prioritizing and development of healthcare
services, resources and policy.

Objectives of the Dissertation
Specific objectives of this study include the following:

1) Representation of the realities and controversies of the genomic healthcare
environment, genomic testing and motivations of Direct-to-Consumer (DTC)
genome testing users (Chapter II);
2) Identification and description of a healthcare conceptual framework (Health
Capability), philosophically aligned with individual health values and goals,
and compatible with examining personal factors influencing individual pursuit
of genome testing (Chapters II and III);
3) Development of a concept mapping for the Health Capability model to
represent the principle concepts (including health status and health values, as
described in the literature review), their proposed relationships, and added
elements philosophically consistent with Health Capability and relevant to the
dissertation research (i.e., access to resources outside the healthcare system,
e.g., DTC laboratories) (Chapter II: current concept mapping; Chapter III:
earlier version as submitted with an article for publication);
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4) Investigation of the concept of perceived health status, how it is defined and
operationalized, and the nature, types, strengths and limitations of approaches
and instruments used to measure, represent, interpret and apply this concept
(Chapter IV);
5) Description of the original research categorizing and characterizing DTC
genome testing users by health status groups based on an individual’s
perceived health versus a medical perspective of health status (Chapter V);
6) Description and comparison of relationships/associations between health
status categories of DTC users and the following: 1) reasons (motivations) for
genome testing, 2) socio-demographic factors, 3) perception of health risk,
and 4) health value of genomic information (Chapter V);
7) Initial exploration to identify and present previously unknown individual
reasons/motivations for pursuit of genome testing, based on answers to open
text questions (Chapter V);
8) Evaluation of research findings and dissertation processes, including
suggested modifications related to Health Capability and the proposed concept
mapping, strategy(s) for choice and use of perceived health status measures,
and discussion of implications for clinical practice and future research
(Chapter VI).

5

CHAPTER II
GENOMICS HEALTHCARE ENVIRONMENT, CONCEPTUAL FRAMEWORK FOR
RESEARCH AND LITERATURE REVIEW

Background: The Genomics & Healthcare Environment
Biomedical advances engendered by the Human Genome Project (HGP),
spanning whole genome sequencing (WGS), evolving technology and bioinformatics,
have opened new horizons for healthcare. These include the following: 1) diagnosis of
previously unknown or complex disorders (ACMG, 2012; Gahl et al., 2011); 2)
assessment of common conditions such as cancer for risk, treatment and prognosis (e.g.,
colon cancer) (National Comprehensive Cancer Network (NCCN), 2014); 3)
identification of pharmacogenetic variation important to drug therapy; risk screening for
early identification, risk management and prevention (Botkin et al., 2010; Do et al., 2011;
Kwon et al., 2010); and, 4) genome panels, e.g., related to neuromuscular and
cardiovascular conditions (AmbryGenetics, 2012; Marian, 2012). Genomic factors can
now be identified in association with low but increased risk for complex and common
disorders impacting large numbers of people (Offit, 2011).
Genome testing offers a unique opportunity for personalized DNA-based health
risk assessment with test results promising information potentially impacting individual
health, risk management and prevention strategies (Berg, Khoury, & Evans, 2011).
These capabilities, advances and potentials are not only published in the scientific
literature, e.g., DTC testing that identified a previously unsuspected mutation having
clinical significance (Personalized Medicine Coalition, 2011; M. E. Roberts, Riegert-
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Johnson, & Thomas, 2011), but are a daily part of mass media news (Grogan, 2014),
online information (Landro, 2013), social networking, and marketing efforts (ScottH,
2013) raising consumer awareness and interest in genome testing. Genomic testing could
conceivably be so powerful an influence as to transform medicine and healthcare (Evans
& Green, 2009).

Issues and Controversies: Healthcare Model, Policies and Individuals
Consistent with the biomedical model and healthcare policies, recommendations
advise limiting whole genome testing to patients assessed by a healthcare provider,
meeting eligibility criteria for a specific diagnosis or targeted genetic risk, and based on
guidelines (American College of Medical Genetics and Genomics, 2013; American
College of Medical Genetics and Genomics (ACMG), 2012; Botkin et al., 2010; Graves,
Peshkin, Luta, Tuong, & Schwartz, 2011; Skirton, Goldsmith, Jackson, & O'Connor,
2012). Third party payers’ policies for genetic testing are limited, targeting specific
conditions or approaches for medically justified exceptions. Coverage does not include
full genome testing for identification of risks (BlueCross BlueShield, 2014;
UnitedHealthcare, 2014). These professional guidelines and coverage policies reflect
concerns for potential harms to patients, lack of evidence to support clinical benefit
beyond targeted applications or that risk translates to disease, and decisions based on
economic healthcare realities (e.g., limited resources).
Consumers committed to genome testing must take the initiative to obtain this
testing on their own. Direct-to-Consumer (DTC) genomic testing (NHGRI, 2012) is
available to anyone, without involvement of a licensed practitioner, via DTC labs and the
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Internet (GPPC, 2011). Until recently (May, 2014), despite Federal Drug Administration
cautions and prohibitions (Gutierrez, 2013), a few DTC labs offered consumers healthrelated genome testing and information (for as little as $99 at one lab that included
interpretative reports and raw genomic data) (23andMe, 2014b), as an option among
“packages” such as ancestry and paternity testing (Clarke, 2013; Hensley, 2013; Wagner,
2013). This latter lab stipulates that it no longer provides health reports at the present
time (although raw genomic data is still generated). The ultimate fate of individual DTC
health-related genome testing, in general, is yet to be determined. Individual independent
use of DTC genome testing is highly controversial (Caulfield, 2011; Evans & Khoury,
2013; R. C. Green & Farahany, 2014; Personalized Medicine Coalition, 2011). Issues
span healthcare, ethics and individual rights (Rivkin & Grossman, 2013), consumer
knowledge and related needs (Hahn et al., 2010), public health, laboratory reporting of
risk (Bloss, Topol, & Schork, 2012; Imai, Kricka, & Fortina, 2011), evidence (or lack)
for action ability based on genomic profiles (Janssens et al., 2008; Janssens, Wilde, &
van Langen, 2011), provider readiness for integration of genomics (Evans & Green,
2009; Frueh, Greely, Green, Hogarth, & Siegel, 2011; Li, 2011; McBride et al., 2009),
and gaps in policy, standards and regulatory arenas (Caulfield & McGuire, 2012; Frueh et
al., 2011; Hauskeller, 2011; Kontos & Viswanath, 2011). Meanwhile, evidence mounts
supporting the unique value of genomic information and the integration of risk testing
into health assessment and healthcare based on its potential for broader applications to
health promotion (Ashley et al., 2010; Botkin et al., 2010; Korf, 2012; Manolio et al.,
2013).
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Summary & Impact on Dissertation Study
A definitive gap exists between what genome testing is authorized, regulated and
deemed of clinical utility by the healthcare system (Palomaki et al., 2010) and is covered
by insurance policies (Graf, Needham, Teed, & Brown, 2013), versus what is of possible
individual value and personal utility (Bunnik, Schermer, & Janssens, 2011; Grosse,
McBride, Evans, & Khoury, 2009), is/has been accessible via DTC laboratories (Genetics
& Public Policy Center, 2011; Graf et al., 2013) and has some professional and advocacy
group support (Caulfield, 2011; Personalized Medicine Coalition, 2014; The Lancet
Editorial, 2012). Although the consumers’ ability to obtain DTC health-related genomic
testing in the future might appear to be diminishing (23andMe, 2014b; FDA, 2014;
Gutierrez, 2014; National Human Genome Research Institute, 2014), the final policies are
yet to be determined. This is dependent upon not only U.S. FDA regulatory authority
(National Human Genome Research Institute, 2014; Shuren, 2010; Wagner, 2013), but
also policies in process, potential constitutional challenges (Rivkin & Grossman, 2013),
and laboratory-related decisions at international levels. This situation, however, does not
change the very relevant questions posed in this dissertation research, nor more
importantly, the broader knowledge that may be gained from this singular population and
study of self-initiated DTC genome testing users.
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Framing the Research: Questions & Hypotheses
Research Questions
What motivates people to seek genome testing independent of their healthcare
providers? Why do they pursue this controversial testing? Are they the “worried well”
(Garfield, 2006), are they cases illustrating discrepancies between health status as
perceived by individuals versus healthcare system assessment criteria (Kivinen et al.,
1998; Okosun et al., 2001) and/or are they proactive prevention-oriented persons whose
needs are not met in the context of a disease-oriented biomedical model (Juengst et al.,
2012; Personalized Medicine Coalition, 2014)?
Do individually perceived health status and individual health values impact
health needs, motivations and actions in persons who independently pursue genomic
testing and information, regardless of health status and values determined by healthcare
system and biomedical criteria? Is there personal health value to genomic information
beyond bio-medically defined and determined use & value?

Research Hypotheses (See Figure 2.1 for hypotheses and relationships)
Hypothesis 1: Discrepancies exist between an individual’s perceived general
health status and health status as defined by healthcare system measures (existence of a
medical diagnosis).
Hypothesis 2 (null): There will be no difference in motivation(s) for pursuit of
genome testing between health status groups stratified by individual perception of health
and healthcare system measures (existence of a medical diagnosis).
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Hypothesis 3 (null): There will be no difference in socio-demographic factors
between health status groups stratified by individual perception of health and healthcare
system measures (existence of a medical diagnosis).
Hypothesis 4 (null): There will be no difference in perception of risk between
health status groups stratified by individual perception of health and healthcare system
measures (existence of a medical diagnosis).
Hypothesis 5 (null): There will be no difference in health value of genomic
information between health status groups stratified by individual perception of health and
healthcare system measures (existence of a medical diagnosis).

Research Rationale and Justification
By categorizing health status as a combination of an individual’s perceived health
and health status using healthcare system measures (i.e., existence of a medical
diagnosis), and examining the identified subjective health-related variables, associations
between health status groups and their distinguishing factors may be identified. This
study has the potential to contribute new knowledge and understanding about human
motivations in seeking and using health-related services such as DTC, as well as
impacting and committing to health-related behaviors, relevant to clinical practice and
research. The study findings may contribute to informing future strategies for screening
and assessment, especially for individuals who challenge the healthcare system, such as
the apparently healthy (e.g., the worried well, versus the early ill, versus the preventionoriented). Implications, however, extend to other areas of identified need in healthcare.
These include facilitating practitioner and individual discussions and decisions related to
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individual health priorities (McGuire, Diaz, Wang, & Hilsenbeck, 2009), approaches to
risk assessment and management, targeted interventions and options, effective allocation
of healthcare services and resources (e.g., avoiding treatments, procedures and
expenditures that do not have individual health value) (Ruger, 2010), and integrating
measures for evaluation of healthcare services and outcomes relating to both clinical
utility and personal utility since both impact services and policy development (Bunnik et
al., 2011).
The dissertation study’s unique dataset of 1,455 Personalized Genomics study
survey respondents (R. Green & Roberts, 2012b), all who self-initiated DTC genomic
testing, serve as a natural, uncontrolled population to learn about subjective individual
factors potentially influencing independent pursuit and interest in using health-related
testing and services (i.e., genomic testing), but also potentially contributing to informing
and advancing healthcare in a broader realm, as noted above.

Conceptual Framework: Health Capability
A healthcare model and conceptual framework is needed whose tenets
acknowledge individual health values and goals, and include primary concepts of the
current dissertation study. This model must support inclusion of individual (subjective)
criteria in determining health goal achievement, allow for individual access to healthrelated resources beyond the traditional healthcare system, foster health promotion and
prevention on an individual level, and define health values and successful outcomes by
other than economic measures. A model integrating these dimensions has been
recommended previously (J. P. Sturmberg, O'Halloran, & Martin, 2012). Given an
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empowered public, evolving advances in bioinformatics and technology, a healthcare
system expected to meet the health needs of individuals and the general public, and
economic realities, any meaningful model must also be systems-oriented and supportive
of communication, collaboration, shared responsibility in decision-making and policy
development involving all stakeholders (Li, 2011; Joachim P Sturmberg, 2007).
The Health Capability conceptual framework meets these stipulated criteria. This
healthcare model is discussed in detail in Chapter III. In this chapter, a conceptual
mapping (see Figure 2.1) is proposed, presented and discussed as the basis for organizing
key concepts, representing their relationships and identifying the focus of the literature
reviewed later in this chapter.

Concepts, Relationships and Study Foci
The principle tenets and concepts of the Health Capability conceptual framework
include individual health values, health status and health functioning, and health goal
achievement (Ruger, 2010) (see Figure 2.1). Their relationships were not specified in the
original conceptual framework, or subsequently. Thus, consistent with current study
hypotheses, these concepts are depicted as interrelated, being joined by a heavy solid line.
A Health Capability profile provided the internal and external influencing factors (Ruger,
2010). The major categories of which are summarized in Table 2.1. These internal and
external factors are listed within overlapping hashed boxes in Figure 2.1, thus
representing a postulated dynamic interplay. The area within the red-hashed irregular
borderline identifies the current study focus. Solid blue lines represent connections
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Table 2.1: Health Capability Profile*: Influencing Factors.
INTERNAL

A.
B.
C.
D.
E.
F.
G.
H.

EXTERNAL

Health status & health functioning
Health Knowledge
Health seeking skills and beliefs, self-efficacy
Health values and goals
Self-management; ability achieve health outcome
Effective health decision-making
Intrinsic motivation to achieve health outcomes
Positive expectation: achieving health outcomes

A. Social norms
B. Social networks and social capital
C. Group memberships
D. Material circumstances
E. Economic, political &social security
F. Utilization/Access to health services
G. Enabling public health & health sys
*Adapted from Ruger, 2010, p 45-46.

between the concepts, factors or components that were identified by the author. Hashed
blue lines represent connections that include a factor or component proposed in my
current study. Hypotheses, denoted by an “H” and the hypothesis number, are in small
red boxes positioned with the corresponding concepts and relationship. Based on
Hypothesis 1, the proposed influence of individual perceived health (highlighted in
yellow in the text box in the left middle of Figure 2.1) has been added and connected by a
blue-hashed line to Health Status. Similar, for Hypothesis 4, the propose influence and
connection between Health Status and Personal Measures of Risk (highlighted in yellow)
is represented by a hashed line. Hypothesis 2 and Hypothesis 5 are represented by solid
lines between concepts and factors. Hypothesis 3 represents an association between
Health Status and components involving selected external factors (socio-demographic
based on survey data). Resources available outside the traditional healthcare system are
represented as an extension (hashed line) of existing resources, on the right side of Figure
2.1. This component, specifically the DTC genome testing box, is not contained within a
red-hashed border but instead is highlighted in blue (lower right of Figure 2.1) since it
defines the primary eligibility criteria for study participants and identifies that all pursued
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this route. Study concepts, highlighted in yellow, are numbered and correspond to the
literature review later in this chapter.

Conceptual Framework Adaptations
Two conceptual framework adaptations were done for this study for the purposes
of operationalization and model extension (i.e., genomics and prevention). First, health
status and health functioning, represented in Health Capability collectively as one entity
within internal factors, is reflected in my proposed Concept Mapping (Figure 2.1) as
having two facets. The first facet measures, as designated by Ruger (Ruger, 2010) and
represented in Figure 2.1: 1) self-reported health functioning (e.g., as measured by the
SF-36, mental functioning and physical functioning (McHorney, Ware John E, Lu, &
Sherbourne, 1994; Ware, 2009)), and 2) measures of health conditions (e.g., biomedical
markers, diagnoses, diseases including mental health) and extrinsic risk factors (e.g.,
smoking, exercise, diet, drug use, obesity). Although these two types of measures
recognize the existence of both physical and mental health, and are “self-reported”, the
instruments and measures offered are from the perspective and criteria of the healthcare
system. One represents a measure of health functioning (not health status). The other set
of measures is based on established medical tests, measurements and guidelines,
including representing (and limiting) risk factors to a medical model context and its
expected health-related behaviors. In contrast, the proposed model addresses a gap in
understanding of the individual perspective of (their) health status (highlighted in yellow,
and connected by a blue-hashed line to Health Status), regardless of that as assessed or
assigned by healthcare system processes and measures. Not to incorporate such
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information seems contrary to the Health Capability framework’s primary tenet of
commitment to individual health, values and goals.
The second modification is a re-framing of health values as a primary concept, as
opposed to simply representing and limiting it under internal factors (see Table 2.1). This
proposed approach allows for: 1) examining and comparing the interpretation of health
status based on a biomedical model and criteria versus an individual’s perceived health
status, and 2) examining a direct relationship between an individual’s health status and
health values as potential motivators of health action/behavior toward achievement of
health goals.

Review of Literature
The goal of this literature review is to: 1) provide the background, current status
and relevant perspectives of the dissertation study’s primary concepts; and, 2) identify
and discuss the conflicts and gaps in the existing research, literature and perspectives.
The concepts are presented in the order of historical development and the evolution of
this dissertation. These are represented in Figure 2.1 by superscripts in uppercase letters
adjacent to the corresponding highlighted concepts. The literature review also provided
the basis for operationalizing the key concepts into measurable, delineated constructs.

Motivation (and Genomic Testing) (Figure 2.1, Superscript A)
Motivation, an internal factor of Health Capability, has been the subject of several
DTC genomic testing studies to gain an understanding about the individual’s interest and
reasons for pursuit of genome testing. The systematic review of the literature, including
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qualitative and quantitative studies of DTC users, identified the following themes,
reasons and desires for individual pursuit of genome testing: curiosity, health-related
(e.g., disease risk, risk factors), specific disease related (e.g., personal diagnosis;
condition in the family), health promotion, gaining information about oneself, genealogy,
helping others, contributing to research, and recreation-related (Goldsmith et al., 2012;
Gollust et al., 2011; Su, Howard, & Borry, 2011).
However, the findings of these studies are limited for multiple reasons spanning
the nature and extent of the sample, the population or data source, the study structure, the
survey or instrument, and inherent or researcher biases. Specific reasons include the
following: 1) study populations involving small and/or convenience samples (Bloss et
al., 2010; McBride et al., 2009; Su et al., 2011); 2) participants who may not represent the
stated population (i.e., candidates for genome testing as opposed to actual users, or
persons who pursued testing because it was free in contrast to self-initiated genome
testing users who pay for testing) (Kaphingst et al., 2012; D. Kaufman, Murphy, Scott, &
Hudson, 2008); 3) participants not representative of the general population (e.g., persons
having an advanced science background or profession, working in the healthcare
industry, or the majority having a college education) (Bloss et al., 2012; Su et al., 2011);
4) discrepancies based on the source (Goldsmith et al., 2012) of data (e.g., participant
answers in conjunction with the labs they used versus postings on outside sites) (Su et al.,
2011); 5) limited percent of survey responders (Bernhardt et al., 2012); 6) surveydesignated answer options for pursuit of testing (Facio et al., 2011); and, 7) potential
researcher biases, as with interpretation of written motivations (Goldsmith et al., 2012;
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Su et al., 2011). For example, a participant’s stated reason for testing is interest in
knowing one’s genome, and that may be classified as curiosity; however, the underlying
motivation was concern, hope and curiosity to gain information that might explain
existing, or undiagnosed symptoms.
There is a dearth of large-scale genomic testing studies related to motivation (and
self-efficacy) (Keller et al., 2010), most notably involving actual DTC genomic risk
testing users who self-initiated testing (Bloss et al., 2010), with limited exceptions.
However, the Personalized Genomics (PGen) study of 1648 self-initiated DTC genome
testing users (R. Green & Roberts, 2012b) found that motivation for DTC genome testing
varied by self-reported health status (R. C. Green et al., 2013) with interest including not
only risk identification, but also confirmation and etiology of an existing diagnosis
(Meisel et al., 2013). Another large-scale study, the Scripps Genomic Health Initiative
(SGHI), found that 82% of participants would want to know risk findings for nonpreventable conditions (Bloss et al., 2010), although this was not part of the study. This
is consistent with results and expectations of another study (Michie, Henderson, Garrett,
& Corbie-Smith, 2011). Other studies supported health promotion, adopting a healthier
lifestyle, and ability to take responsibility for future health as motivators for seeking and
using genomic information (Cherkas, Harris, Levinson, Spector, & Prainsack, 2010;
McGowan, Fishman, & Lambrix, 2010).

Summary
Although the findings of DTC genomic testing research has contributed to initial
understandings related to motivation, studies are few in number with significant
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limitations. Specifically these studies: 1) cannot be presumed to represent individuals
who pursue DTC “on their own”; 2) cannot adequately inform an understanding of health
values, perception of health and risk, and health needs as motivators for genome testing
(or future health behaviors); and, 3) are compromised in their ability to inform clinical
practice, prevention strategies and policy directions (Bloss et al., 2010; Goldsmith et al.,
2012; Goldsmith, Jackson, O'Connor, & Skirton, 2013).

Health Values (Figure 2.1, Superscript B)
The gap in understanding individual interest in, and motivation for, pursuit of
genomic testing may involve even more basic human factors, such as individual health
values. A representative definition of human values involves “… an enduring belief that
a specific mode of conduct or end-state of existence is personally or socially preferable to
an opposite or converse mode of conduct or end-state of existence” (Rokeach, 1973).
This same author purposely avoided use of the terms "ought", "should", and "conceptions
of the desirable", discussed many types of values, yet health values was not included.
A systematic review of the literature was performed using PubMed, PsychINFO,
CINAHL and Cochrane databases. Since PubMed Medical Subject Headings (MeSH)
does not include individual health values, a three-step process was used to identify
relevant records. First, the term health values were searched as a keyword, identifying
107, 859 records. Next, a search using the MeSH terms individual or personal resulted in
7,939,611 records. Third, a search stipulating the union of these two sets resulted in
64,430 records. In order to identify records specific to genomic information and testing,
a series of searches was done using these, as well as five other genomic-related MeSH
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terms. By combining this result with that for individual health values, 337 records were
identified (limited to humans). Six additional records were identified through other
sources, i.e., a university library resource expert and references cited within a health
values-related text, for a total of 343 records. These records were screened by title and/or
abstract content. Exclusion criteria included the following: records lacking mention, or
the essence, of health values, individual health perspective or personal value of
genomic/genetic information. From a complementary perspective, the inclusion criteria
retained records that used these previously stated terms, or their essence, as well as
research involving focus groups and qualitative studies of individual health views. This
resulted in a final selection of 30 records for full review, including qualitative and
quantitative studies, perspective articles and commentaries. Several articles or studies
did not actually address individual health values or used values from a different context,
such as equating it with knowledge, and these were excluded. Corresponding searches of
PsychINFO, CINAHL and Cochrane databases did not identify any further records.
Individual Perspective: Very few studies addressed individual health values as a
subjective personal concept with qualitative aspects (e.g., what the subjective elements
are, their relative importance), and their relationship to interest in or pursuit of genetic
testing. Studies of relevance typically used a survey or targeted focus groups for specific
disorders or conditions, identifying value or belief themes that influenced interest in
genetic testing or information (Doukas, Fetters, Coyne, & McCullough, 2000; McBride et
al., 2009; Pivetti, Montali, & Simonetti, 2012). Although these studies spanned very
different populations, from men of various ethnicities aged 18-90 related to prostate
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cancer risk and gene testing, to 20 pregnant women and new mothers related to uptake of
prenatal genetic testing (PGT), the identified themes and reasoning were similar in
nature. The essence of themes were the following: 1) usefulness and benefits of
information (e.g., for making choices, preparing, family planning, taking action such as
changing diet or exercise; 2) interest in and concerns about susceptibility, risks and
consequences; 3) beliefs about barriers; and, 4) issues of morality and trust (Doukas et
al., 2000; McBride et al., 2009; Pivetti et al., 2012). These studies were few in number,
limited to specific conditions, have small sample sizes and/or only partially address the
issue of individual health values; however, they also attested to this concept’s influence
and the need for further research.
Cultural and Societal Influences: The cultural and societal influence on values
and perceptions was also evident. What is perceived as important to an individual or
community group may be of little value by healthcare system standards, and vice-versa
(e.g., knowledge of risk prior to symptoms versus reduction in mortality). This
perpetuates a frustrating, costly, resource draining and ineffective cycle for practitioners,
patients, educators and policy makers. Studies, such as those involving Fragile X genetic
screening of children in the Colorado schools’ special education classes, found that
interest in genetic testing reflects cultural beliefs regarding the importance of genetic
information and expectations about future possibilities (Nelkin, 1996). The author also
posits that the media fosters a public impression of social meaning to genetic testing that
it may support individual needs. Whether or not one agrees with this position, there is no
question about the existence of marketing related to the value and potential of
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genetic/genomic information and testing, an increasing public awareness and interest, and
the healthcare view of its limited clinical utility (Ducournau, Gourraud, Rial-Sebbag,
Bulle, & Cambon-Thomsen, 2011; Jordens, Kerridge, & Samuel, 2009).
Healthcare System Perspective & Issues: The literature review identified one
relevant large scale study involving 12 focus groups and 97 healthcare providers (i.e.,
genetic counselors, physicians and nurses in four different geographic areas) that
demonstrated discrepancies and conflicts encompassing sixteen major ethical and
professional domains (Veach, Bartels, & LeRoy, 2001). Value-associated conflicts were
among the second and third most common issues, spanning intrapersonal (professional
with self), interpersonal (between professional and the patient, or a colleague), and extrapersonal (among patient family members) relationships. It is noteworthy that all
examples of values’ conflicts (5) provided by the study authors had a moral basis. Yet
the common occurrence of conflicts in the broader spectrum of health-related values,
especially between healthcare providers and patients as well as healthcare providers with
each other, supported the relevance and need for studies to examine individual health
values. Such information relates to the provision of meaningful healthcare services,
prioritization and allocation of healthcare resources, expectations for patient health
behaviors and outcomes, support for individual healthcare values, and the development of
effective policy (Ruger, 2010; J. P. Sturmberg et al., 2012).
Health Values as an Economic Measure: An economic perspective of health
value was a common component among the identified studies. In healthcare, value is
often defined as an outcome/cost ratio, such as cost-effectiveness (CE) or incremental
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cost-effectiveness ratio (ICER) (Kwon et al., 2010; Woolf, Lewin, Marks, Fielding, &
Sanchez, 2009). CE may be based upon the achievement of significant differences in
outcomes, such as morbidity, mortality or health benefits, often within a given time
frame, related to a specific treatment, strategy or technology (Tilburt et al., 2011). An
economic view of health value also exists in the prevention context. Two examples are
the assignment of a CE threshold of $50,000/year of life gained in the context of breast
cancer treatment and testing (Kwon et al., 2010), and individual willingness to pay for
services (i.e., genetic counseling, information and testing services) based on the
contingent valuation method (Eden et al., 2013). Individual values and quality of life
(QOL) factors are typically not included (Tilburt et al., 2011). A quasi-economic view of
health values, captured by the idea of worth or tangible value of genetic/genomic
information from the framework of exchange, gift and genetic responsibility theories,
was demonstrated in a study of 752 donors of specimens for genetic research (Michie et
al., 2011). This study’s results, despite the focus on altruistic motivation while respecting
a monetary value of donations, distinctly supported the existence of underlying individual
health motivations and expected personal health value for participants. Of donors, 70.8%
wanted to find out information about their own health, although informed consent
specified that was not an intended use for the specimens. Donors also spoke of their
specimens in the context of diagnosis rather than research use, with an expectation of
results, consistent with a personal value to their genetic information.
Summary & Discussion: The studies reinforced the existence and influence of
underlying individual health values, the expectation and/or desire for personal
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information, the potential (or perceived) value of genomic information to the individual,
and the necessity for further research to gain a better understanding of future applications
in healthcare. Existing gaps include the individual (patient, researcher, system)
subjectivity in defining and operationalizing health values, its relationship with other
personal health components (e.g., perceived health status), and its contribution to an
individual’s motivations, decisions, actions and expectations for healthcare information
and rights of self-determination, including the pursuit and use of genomic testing
(Nyrhinen, Hietala, Puukka, & Leino-Kilpi, 2009). There was also a distinct gap in
understanding and perspective involving individual health values related to clinical utility
versus personal utility (Bollinger, Scott, Dvoskin, & Kaufman, 2012; Bunnik et al., 2011;
Grosse et al., 2009). A practical question arises about the use of alternate definitions and
measurements for health value, specifically focusing on individual subjective health
values, that may better delineate personally relevant influences, how they interrelate with
other subjective personal health components (e.g., perceived health status), individual
needs and health goals, as well as the value and personal utility of genomic information
as it relates to individual health choices and behaviors.

Perceived Health Status (Figure 2.1, Superscript C)
A systematic review of the literature was performed concerning the individual’s
perceived health status and this is addressed in Chapter IV. The review also includes
review of literature and discussion about the two main methods used to capture this
construct, specifically a single question or a measurement instrument. The focus in this
section is restricted to relevant foundational and contextual information.
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The healthcare system traditionally has viewed health status using the biomedical
model, focusing on the presence or absence of symptoms, illness or increased risk as
defined by the presence of objective scientific evidence to make a diagnosis, justify
intervention and determine treatment (Borrett, 2013). Many situations do not meet these
standards. The need for examining health and health status from the subjective individual
perspective is recognized, yet the healthcare system is struggling with how to do this,
what models to use, what values to include and the mechanisms to use for evaluation
(Loughlin et al., 2013).
Studies that include an individual’s perspective of health status typically involve
the use of a survey or questionnaire that limits capturing this construct to a single
qualitative, yet quantitatively measured, item or focus for analysis. For example, one
study of DTC users of genomic testing asked participants to rate their (overall) health
using a 5-point Likert-type scale ranging from very poor to very good (Bloss et al., 2010),
while a study of African-American males focused on cardiovascular disease examining
health status, but from the context of health abilities (and functioning) using a health
practices scale (DeCuir, 2007). Health status and health values were frequently framed in
the context of health risks, risk likelihoods and binary situations (Wang et al., 2009).
These risk and binary approaches lack appreciation of the broader and qualitative
dimensions of health values and individual freedoms, and foster an all-or-nothing stance
that minimizes the potential contribution of research in multifactorial and complex
common disorders, which includes predictive genomic testing (Boenink & van der Burg,
2010).
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Although the search focus was health status, the majority of records identified and
reviewed were disease or risk focused, involving quantitative or mixed methods studies
that included measures of perceived health status based on the study focus or need. The
most frequently used instrument (8/19; 42%) for evaluating perceived health status was
the SF-36 (Foottit & Anderson, 2012; Funk et al., 1997; Gartsman, Brinker, Khan, &
Karahan, 1998; Hunter, McKee, Black, & Sanderson, 1995; Lindsay, Smith, Hanlon, &
Wheatley, 2001; Mattera et al., 2000; McHorney et al., 1994; Ware, 1976, 2009). This
instrument has been suggested for measuring health status and health functioning in the
Health Capability conceptual framework (Ruger, 2010). The SF-36 encompasses 36
questions, spanning eight scales (physical functioning; role-physical; bodily pain; general
health; vitality; social functioning; role-emotional; and mental health), plus the perceived
general health status item. The repeated use of this measure across more than 4,000
studies has supported its validity and reliability (Ware, 2009). This is addressed, together
with other instruments in common use, in Chapter IV.
These instruments have limitations related to the following: 1) the limited
number of questions, reflecting the inability to cover all desired health status related
content areas; and, 2) the survey structure in that questions provide all answer choices,
without open ended questions, thereby precluding the ability to capture unique individual
subjective concerns or issues. These issues may alter the understanding of an
individual’s perceived health status, and their contribution to influencing health related
needs and actions, such as the decision to pursue genomic testing. Based on this search,
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no instrument was identified that encompassed an individual’s perception of health status,
and subjective personal health values, concerns and goals.

Discussion
The need for further research to examine and foster understanding about the
individual’s reasons for independent pursuit of genome testing was demonstrated by the
results of a literature review (Goldsmith et al., 2012) attesting to gaps, biases, lack of
actual users and likely underrepresentation of persons pursuing DTC genome testing.
These findings also lend support to the current study’s proposal that an individual’s
perception of health is a complex construct composed of many components, differentially
relating on an individual level to motivation, health values and goals, and health
behaviors. The elements identified, yet not combined or examined for potential
interactions in a research study thus leaving unanswered questions, include the following:
physical and/or psychological, i.e., disorders or symptoms (Heshka, Palleschi, Howley,
Wilson, & Wells, 2008); perceived and actual health risks, such as for multifactorial
conditions (Zeggini et al., 2008); familial conditions and genetic aspects (Heshka et al.,
2008; O'Neill et al., 2009); environmental influences, as with Parkinson’s disease (Do et
al., 2011); lifestyle choices, such as smoking (Janssens et al., 2011; Saudny, Cao, &
Egeland, 2012); and, individual goals, such as health promotion (Juengst et al., 2012;
Lea, Skirton, Read, & Williams, 2011). Awareness of these components and possible
interactions challenge previous research findings based on simplifying and restricting
health status to representation as a biomedical, or single entity.
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These health-related components are noted in the Concept Mapping, Figure 2.1,
as comprising Individual Perceived Health Status. This study incorporates only the
perceived risk component (see following). The other components will be examined in
future research.

Risk Perception (Figure 2.1, Superscript D)
Perception of health risk is a factor associated with individual pursuit of genomic
testing (Gollust et al., 2011). Most studies use the terms perception of risk, risk
perception and perception of health risk synonymously without defining these terms, but
instead imply their meanings based on the study context, population focus and/or
operationalization of items measured (Hahn et al., 2010; D. J. Kaufman et al., 2012;
Lerman, Rimer, & Engstrom, 1991; Lipkus, 2007; McAllister, 2003; van Maarle,
Stouthard, & Bonsel, 2003; Watson et al., 1999). For example, perception of risk was
used as disorder specific for breast cancer (Watson et al., 1999) and for Alzheimer’s
disease (among others) (Heshka et al., 2008). The single focus of risk perception in these
studies can be viewed as a strength for statistical analysis, yet it is also a limitation if
perception of risk includes qualitative components not sought, measured or recognized as
important to individual health values and goals.
Philosophical Origins and Measures of Risk: Two fundamental views of risk
operate in parallel based on cognitive psychology and neuroscience. There is the
“analytic system” that uses algorithms and norms, and the “experiential system” based on
individual experiences, affect (emotions) and values (Slovic, Finucane, Peters, &
MacGregor, 2004). The former, consistent with a biomedical scientific model, reflects
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objective, reasoned and logical processes that can be measured, quantified and controlled.
The latter reflects individual health values, subjectivity, human dynamics and personal
goals, consistent with valuing genomic information and mapping back to the Health
Capability concepts and principles.
Risk perception incorporates “a situation or an event where something of human
value (including humans themselves) is at stake and where the outcome is uncertain”
(Rosa, 1998), a risk target (self vs. others) (Sjoberg, 2000), and “how concerned we are
about the consequences” (Sjöberg, Moen, & Rundmo, 2004). Three key features
emerged, all subjective in nature, being: assessment of probability, an undesired
event/entity, and concern about the impact of the outcome for self. Individual perception
and interpretation of health risk is paramount. This is not confined to a single, static,
isolated risk factor.
Defining Individual Perception of (Perceived) Health Risk: For the purpose of the
current study, individual risk perception is defined as: Individual recognition or
appreciation of real or believed vulnerability, compromised health status and/or
likelihood of a disease(s), disorder(s) or condition(s) (specific or in general), as either
increased relative to others, or existing to an extent beyond that acceptable to that
individual (BusinessDictionary.com, 2012; Dearborn & McCullough, 2009; Gregory &
Mendelsohn, 1993; Griffith, 2011; Lloyd et al., 1996; McAllister, 2003; "Risk
Communications Bibliography," 2012; Rosa, 1998; Slovic, 1987; Walker, Mertz, Kalten,
& Flynn, 2003; Watson et al., 1999). This definition facilitates the operationalization of
various potential individual influences contributing to an individual’s perception of risk
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(which parallel components relevant to an individual’s perception of health, as noted
previously).
Genetics/Genomic Context: Perception of risk, from a genetic perspective, has
been operationally defined and measured in different ways (Lipkus, 2007). These
included the following: quantification of risk for a specific disease, e.g., cancer, using
numeric measures (comparative; binary; personal; population percentage of risk) (Kelly
et al., 2007); measuring risk likelihood for selected diseases, e.g., as with a Likert-type
scale (Lerman et al., 1991); assessing the extent or category of risk (e.g., present/absent;
high/moderate/low); and, accuracy of individual recall for disease specific numeric risk,
test result or biochemical screening values (Kaphingst et al., 2012; D. J. Kaufman et al.,
2012; van Maarle et al., 2003).
Risk perception research in genetics has examined this phenomenon in
participants, primarily after receiving the results of genetic testing (Heshka et al., 2008;
D. J. Kaufman et al., 2012). A review of the literature on the perceived risk,
psychological and behavioral impacts of genetic testing identified 35 articles and 30
studies (Heshka et al., 2008). No differences were found in risk perception between gene
mutation carriers and non-carriers 12 months post-test, postulating one explanation for
the lack of differences as possible differences in risk perception between these two
groups. A gap in research exists related to the examination and understanding of
perceived health and risk before genome testing, its potential influence on individual
health values, expected results and pursuit of testing, and the impact on health-related
behavior. Although this has been studied to a limited extent, the focus on risk perception
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has been disease/condition specific or based on case scenarios, as opposed to actual
personal results and experience (D. J. Kaufman et al., 2012).

Concepts Assumed in the Current Study (Figure 2.1, Superscripts E and F)
Self-efficacy (Superscript E): This concept, among Health Capability’s internal
factors (see Table 2.1), includes coping behavior, the extent of energy expenditure, and
sustaining in the face of obstacles and aversive experiences, are supported by behavioral
change theory (Bandura, 1977). Self-efficacy is defined as “…the judgments people hold
about their capacity to master specific tasks and to cope with challenging situations (Oles
et al., 2013) (p.48). Self-efficacy has relevance to the well-established health-related and
prevention theories including health belief, health locus of control and health capability
(Janz & Bcker, 1984; Norman, 1995; Rosenstock, 1974; Ruger, 2010). Studies involving
self-initiated testing and genetic risk concerns support the concept of self-efficacy as
relevant to the pursuit and/or use of genomic testing (Grispen, Ronda, Dinant, de Vries,
& van der Weijden, 2011; McGowan et al., 2010). Thus, persons whose health goal was
to secure genome testing, and who independently accomplished this testing despite
traditional healthcare system barriers, all exhibited self-confidence and self-efficacy.
Health Knowledge (Superscript F): Defining and measuring the concept of health
knowledge, an internal factor of Health Capability, was included in several genetics
studies (Haga et al., 2013; Leighton, Valverde, & Bernhardt, 2012). This poses a myriad
of challenges, not the least of which is determining the relevant focus. The gap in
research addressed by this study relates to individual perceived health status, health
values, reasons for pursuit of genome testing and perception of health risk. These
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subjective concepts do not require, or necessarily correlate with, genetics knowledge.
Genetics knowledge will not be examined in the current study. As further justification
for this decision, previous studies of DTC genome testing users has consistently shown
participants to tend to have higher levels of education than the general population, to tend
to understand that genome testing results relate to potential risks not outright diagnoses,
and that discussion with healthcare providers is recommended before taking any healthrelated action. These studies also demonstrate inherent biases, such as the nature of the
questions posed, interpretation of answers and scoring, use of accuracy as a surrogate for
knowledge, the nature of knowledgeable comparison groups, and assumed gain in
knowledge if research educational materials are accessed (Keller et al., 2010; Leighton et
al., 2012; van Maarle et al., 2003).

Summary and Relationship to Other Chapters
This chapter described the genomics and healthcare environment, the increasing
use and evolving potential of genome testing, and the issues and challenges related to
individual pursuit of this testing. Research questions and hypotheses address the
components potentially influencing individual self-initiated pursuit of DTC genome
testing, from the perspective of an individual’s subjective perception of their health
versus health status based on healthcare system parameters. Other possible subjective
influences include motivating elements, individual health values and goals, and perceived
risk. The concept mapping proposed in this chapter operationalizes the conceptual
framework, Health Capability. Relevant concepts and components of the Health
Capability model related to the study are presented, along with corresponding literature
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reviews. These concepts include motivation, health values, perceived risk and perceived
health status. Perceived health status is the main concept based on literature reviews.
The concept map is examined along with approaches and instruments to measure this
concept. This background and processes lead to the study presented in Chapter V. The
DTC genomic testing research supports the importance of concepts essential to this
dissertation research study and to Health Capability. However, if and how these concepts
and components interrelate, influence health-related priorities and decisions, impact
health action and behavior, and compare with traditional perspectives of health status
have not been examined. Data from the PGen study of DTC genome testing users (R.
Green & Roberts, 2012b), forms the basis for this study. It offers an opportunity to
address these questions in self-initiated users with no input from healthcare providers or
researcher-based influences prior to their decision to pursue genome testing. The broader
implications of this research are addressed in Chapter VI.

34

CHAPTER III
PERSONALIZED GENOME RISK TESTING: EXAMINING A MODEL TO INFORM
AND AMELIORATE THE DICHOTOMY FACING HEALTHCARE

Introduction & Background
This chapter is an article submitted for review and publication to the Journal of
Health Services Research & Policy. The following pages are copied from the PDF file,
exactly as submitted in compliance with journal requirements.
The content of this article complements and extends information on the Health
Capability conceptual framework. This model encompasses the concepts and
prioritization of individual health values and goals, from both a philosophical and a
practical basis. These are integral to this study. The concepts/constructs of perceived
health status, health values (and goals), health functioning and health agency relate
directly to the users of Direct-to-Consumer (DTC) genomic testing. In the Health
Capability profile, internal and external health-related factors are recognized as
influences on the individual at different system levels (individual, family/community,
healthcare systems, and societal/governmental). However, a concept map of these
relationships does not exist. This article includes a proposed structure and relationship of
essential concepts that became the Concept Mapping presented in Chapter II. This
included an expansion of some components for enhanced health-related applications,
such as the context of genomic testing in healthy persons. Components of this map were
tested in the study (Chapter V).
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Figure 3.1: Conceptual model of health capability.
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Figure 3.2: Conceptual process model of health capability.
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CHAPTER IV
PERCEIVED HEALTH STATUS AS A MEASURE FOR ASSESSMENT
AND MANAGEMENT OF HEALTHY PERSONS:
A REVIEW OF THE LITERATURE

Introduction & Background
This chapter is an article submitted for review and publication to the journal
Research and Theory in Nursing Practice. The following pages are copied from the PDF
file, exactly as submitted in compliance with journal requirements and author guidelines.
This article is a systematic review of the literature pertaining to the concept of
perceived health status. It also includes a focused and detailed presentation of
approaches and instruments to measure this concept. Knowledge of this concept,
approaches used to determine its influence, and measurement instruments are essential to
this dissertation and the Health Capability paradigm. This knowledge is relevant to
operationalizing perceived health status, as well as to the data analysis and interpretation
of the study results (Chapter V). The research results will contribute to understanding the
dimensions and influence of perceived health status, its role in the Health Capability
(Chapter III), and its relevance to clinical practice and research. The dissertation study
results related to self-perceived health status (as well as health values, Chapter II) will
also contribute to the further development of a functional/operationalized model for
Health Capability, to assessing appropriate methods and instruments for measuring these
concepts, and possibly to broader applications across traditional and evolving healthcare
(Chapter VI).
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Figure 4.1: Conceptual Model of Health Capability.
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Abstract
Purpose: To: 1) examine health status, categorized by both individual perceived
health and biomedical health (medical diagnosis), for discrepancies and to characterize
group differences, and 2) assess individual perceived health status and health values as
influencing self-initiated genome testing. Methods: 1464 direct-to-consumer (DTC)
genome testing users, participants in the Impact of Personal Genomics (PGen) study,
were classified into four mutually exclusive health status groups. Groups were analyzed
on reasons for pursuit of testing, individual risk perception and health values by Chisquare ( 2), t-tests, ANOVA and correlations. Results: All four categories were
represented, confirming discrepancies between individual and biomedical health status.
One group may represent the “worried well”. Interest in health-related information was
high (98–99%) across all groups. Two items distinguished all groups (interest in
pharmacogenomics information and learning risk for other diseases (p < .001), while
some items distinguished one group. When groups differed, perceived rather than
biomedical health status was often involved, yet both factors demonstrated influences
(variable dependent). Risk perception was moderately correlated (.301) with health
status group. Conclusions: Individual perceived health status and health values are
significant factors influencing self-initiated health action (pursuit of genomic testing),
suggesting benefit of integration and complementarity in effective healthcare practice,
research, models and policy.
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Introduction
Through 2014, an estimated one million persons have pursued direct-to-consumer
(DTC) genome testing, providing them with health-related results1,2. Despite recent FDA
regulatory action currently restricting DTC labs from marketing and providing healthrelated genomic testing3,4, final authoritative determinations are yet to be made5.
Nonetheless, official positions are unlikely to thwart public interest, demands and
expectations regarding genomics in healthcare6-8. Motivations for individual pursuit of
genome testing identified through research span curiosity, desire for information about
health (risks), support for research, genealogy, and fun/entertainment9-13. These results
are limited, however, by factors including recruited or convenience populations, small
sample size, anticipated versus actual genome testing, example cases versus actual
results, equating genetics knowledge with ability to understand or use genomic
information appropriately, use of surrogate measures for subjective concepts (e.g.,
absence of medical diagnosis as individual good health) and the nature of survey
questions9,13-17. This latter issue regarding questions potentially compromises findings
and interpretations in ways not previously appreciated or readily apparent, e.g., what
questions are posed (albeit objective); use of technical or culturally-influenced
terminology; limited, duplicitous or confusing answer choices; and researcher/clinician
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over-simplification or misunderstanding of participant text responses. Thus perpetuating
that “we do not know what we do not know”18.
Important unanswered questions and gaps in knowledge remain. Do individuals
who pursue DTC genome testing deem this information essential to their health and
health management decisions? Do they represent the “worried well”19, or proactive
prevention-oriented persons, neither deemed needy of over-burdened healthcare services?
And perhaps, of most relevance, “Does individual perceived health status (regardless of
biomedical health status) and personal health values act as drivers influencing individual
pursuit of genome testing or value (personal utility20) of genomic information? Answers
to these questions extend well beyond the genomics context.
Perceived health status, although recognized as a powerful predictive factor in
studies of mortality and morbidity21-24, has seen limited exploration in the context of
prevention and health promotion research. In spite of its potential importance, it is
essentially treated as an ancillary or complementary item/measure17,24 rather than as an
integral, and possibly even determinative, factor in individual health priorities and
decisions. Perceived health status, by its subjective nature, must encompass some
internal personal measure(s) for interpretation of one’s health (and/or risks)25 resulting in
perceived gradations of acceptable, unacceptable or choice to ignore. Depending upon
that assessment, an individual may determine whether needs exist and if so, whether or
not to take action. This process also implies the existence of personal health values
(distinct from those of healthcare, e.g., cost/benefit)26 and goals that influence
motivations to action. Thus, individual health-related actions can be viewed as part of an
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interactive process with perceived health status and personal health values and goals,
consistent with the conceptual basis (Health Capability27) of the current study.
The population studied here represents a rare, naturally occurring sample of both
medically diagnosed as well as healthy persons (not as controls), unaffected by the
influence of clinicians, researchers or a controlled study prior to independently deciding
to pursue genome testing, who subsequently enroll in the PGen study28. This study
sought to explore the influence of subjective individual factors, combined with and
distinguished from traditional healthcare contexts, specifically perceived health status,
health values, risk perception17,29-32 and reasons for pursuit of genome testing. This
knowledge relates not only to DTC users, but potentially contributes to identifying
previously unrecognized individual motivations and values that impact many health
behaviors, as well as fostering individual-practitioner partnership and respect in
healthcare priorities and decisions, and more effective use of healthcare resources.

Materials and Methods
Study Design
This study examined survey data from persons who independently pursued directto-consumer (DTC) genome testing and voluntarily participated in the National Institutes
of Health funded Impact of Personal Genomics (PGen) Study 33. The PGen initiative
developed three surveys using items (e.g., multiple-choice, Likert-type) from existing
genetics research instruments with previously demonstrated reliability and validity 14-16,34-39.
Items spanned domains and content relevant to the current study and its conceptual
framework (Health Capability)27, including but not limited to motivations and
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expectations (for genome testing), risk perception, socio-demographics, personal utility,
individual health values, individual medical history, family history and health-related
behaviors. Surveys were completed in 2012, two weeks prior to pursuit of genome
testing (BL), and two weeks (2W) and six months (6M) after testing. This study,
approved by the PGen Review Board, Harvard Medical School, and the Clemson
University IRB, utilized de-identified study-specific data provided in an SPSS format,
primarily from the BL survey with relevant items solely in the 2W survey.

Participants & Survey Dissemination
Potential participants were invited via the health-based social networking site
PatientsLikeMe and a banner on the Pathway Genomics website. Personal genome
testing (SNP analysis), including provision of health-related results, was pursued through
either the 23andMe or Pathway Genomics laboratory40,41. The original PGen population
consisted of 1,838 consenting persons, with 1,648 eligible after eliminating partial or late
received surveys; 1,464 persons completed the second survey and were eligible for this
study. They were categorized into four mutually exclusive health status groups (the
independent variable) based on dichotomizing perceived health and medical diagnosis
status. Participants included males and females, ages 19-94, of different races, ethnicities
and educational, socioeconomic and occupational backgrounds.

Data Analysis
Statistical power was assessed based on the number of eligible PGen participants,
as well as the numbers anticipated for the current study’s groups. This was determined to
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be sufficient for the intended data analyses, with a power of .8 and at a 0.05 level of
significance 42. It is relevant to note that the study variables are qualitative and subjective
in nature, were assessed primarily by Likert-type scale items (with 3-5 choices), and were
suspected to be in an interrelated, interdependent relationship (consistent with this study’s
conceptual framework). Descriptive statistics (mean; standard deviation) and frequency
analyses were done to characterize health status groups (see Table 5.1). Groups were
compared on socio-demographic items, reasons for pursuit of genome testing, risk
perception and individual health values using Chi-square ( 2), t-tests and/or analysis of
variance (ANOVA) (depending on whether these dependent variables were categorical or
continuous). Statistically significant differences identified by ANOVA were subjected to
independent t-tests between two-group combinations to identify the source/s of
significant difference. Original PGen scoring of variables was maintained, or if
modified, variable direction and construct integrity was preserved. Operationalization of
measures is addressed in the Results sections. Limited qualitative data was examined by
query of study-relevant text answers for targeted terms (keywords) to identify and
quantify existence of factors that could impact health status groups and/or interpretation
of results (e.g., mention of undiagnosed health problem, or diagnosis not included in the
survey).

Results
Health Status Groups
Respondents were classified into four mutually exclusive health status groups by
dichotomizing perceived health status and health status based on medical diagnosis.
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Table 5.1. Characteristics of PGen study participants1 included in health status
groups.
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Diagnosis related to presence or absence of any of fourteen survey-specified types of
conditions: arthritis, asthma, cancer, chronic kidney disease, diabetes, eye,
gastrointestinal, heart, high cholesterol, lupus, mental illness, neurological, obesity and
psoriasis. Perceived health status was dichotomized as: good (good, very good,
excellent) or not good (fair, poor). Of 1,464 eligible surveys, two lacking answers for
perceived health status were eliminated, as were another seven noted among the
following health status groups, leaving 1,455 persons:

Diagnosed Ill (DI): 213; one or more diagnoses (mean 4.40; range 1-10) and
perceived health as not good.
Medically Managed (MM): 950; one or more diagnoses (mean 2.75; range 19) and perceived health as good.
Healthy (H): 292; without a diagnosis and perceived health as good.
Health in Question (HQ): 7; without a diagnosis and perceived health as not
good (eliminated due to small size; see Discussion).

Diagnoses types between the DI and MM groups were not statistically different
except for arthritis, eye, gastrointestinal, obesity and neurological conditions (p < 0.05),
and kidney disease (p = 0.05). Socio-demographic characteristics, noting significant
differences on several variables, are summarized in Table 5.1. T-tests clarified most
differences involved the Healthy group. The DI and MM groups had similar mean ages
(51.2 and 50.1, respectively, compared to 37.5 for the Healthy) and percent having
biologic children (54.5 and 55.7%, respectively, compared to 37% for the H). Sex was
only significantly different (p = 0.006) between DI and H groups (69.5% versus 55.5%
female, respectively). Participants were primarily White, 5-6% Hispanic, and minorities
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represented fewer than 5% (African-Americans, Hawaiian/Pacific Islanders, Asians,
American Indians). Income was significantly different (p < 0.001) by t-test comparisons
involving the DI group. Individual decision-making role with healthcare providers
demonstrated the majority, regardless of group, shared in responsibility; however, the DI
and H groups were significantly different (p = 0.034).

Reasons for Pursuit of Genome Testing
Importance of twelve specifically queried reasons for pursuit of genome testing is
summarized in Table 5.2, including five identified as significantly different. All other
items, except one, were uniformly rated as important. Finding out about personal
response to different medications distinguished all three groups (p < 0.001 for both DI
group comparisons; p = 0.037 for MM with H). T-tests identified the DI group as the
source of most between group significant differences (p < 0.01 for personal risk for
disease, creating a better plan for the future, and test seeming fun/entertaining). The
Healthy group was the source of significant difference for only importance of health
condition risk information for children (p < 0.01, with either DI or MM).
A text response to reasons for pursuit of genome testing was queried for keywords
including “undiag…”, “health problem”, “I have”, “unknown” and “health concern” to
identify frequencies of participants expressing desire/hope to get information about
undiagnosed health problems or diagnoses beyond those in the survey. Of 1,352
respondents, twenty-eight instances were identified (see Table 5.2). This information
would have changed health status group assignment for two cases (from H to MM).
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Risk Perception
Risk perception analysis encompassed two approaches. Frequencies
(percentages) of perceived increased risk to develop each of twelve survey-specified
conditions is presented in Figure 5.1. Another twelve conditions are not included due to
poor response rate (< 40%). Figure 5.1 illustrates vertically, by increasing depth of color
of health status group columns, an apparent trend in perceived risk being lowest in the
Healthy, in the mid-ranges in the Medically Managed, and highest in the Diagnosed Ill.
In contrast, cluster patterns across health status groups are represented horizontally in
Figure 5.1 (bracketed, left side), e.g., three conditions at the bottom and four at the top
demonstrating parallels in highest perceived risks across all three groups.
Second, risk perception was captured as a single variable representing the total
number of survey-specified conditions (0-24) that each individual noted as being at
perceived higher than average chance to develop (survey language). This type of additive
approach has been used previously in research43. Group means were significantly
different (p < 0.001). The means (and range of conditions) were: Healthy 1.61 (0-8),
Medically Managed 3.01 (0-17) and Diagnosed Ill 4.36 (0-13). Between group
comparisons by condition, presented in Table 5.3, demonstrate the Healthy group as
significantly different from the DI for all nine conditions and from the MM on seven
conditions. Comparison between the two groups with medical diagnoses (DI and MM)
demonstrated significant differences relating to colorectal and lung cancer, diabetes and
heart disease, despite similar mean ages. Among persons indicating no increased risk for
any of the 24 conditions, 92.4% indicated their perceived health status as good. In
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Figure 5.1: Percentage of Individuals within Health Status Groups at Perceived
Above-Average Chance to Develop Survey-Specified Conditions.
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contrast, 62.5% of persons having no perceived increased risk had one or more medical
diagnoses.
To potentially identify if risk perception was differentially associated with
perceived health status, with health status based on existing medical diagnosis, or with
the combined health status, Pearson correlations were done. Perceived risk was weakly
correlated with medical diagnosis status (.272), was moderately correlated with health
status group (.301) and was moderately correlated (.326) with perceived health status.
This suggests a greater influence by perceived health status. All correlations were
statistically significant at the p = .01 level (two-tailed).

Health Values
Consistent with existing literature, individual health values were operationalized in this
study by items (ten pre-testing and six post-testing) encompassing participant indicated
importance, interest, consideration or value (in the context of genomic testing or
information)27,44. Table 5.4 summarizes the results of answers pre-testing, including
details of the four achieving statistical significance. The DI group was significantly
different from both the MM and H groups on all four items. The MM and H groups were
similar on two of the four, as well as being within 1.5% of each other on three other
items. The Healthy group was significantly different from both the DI and MM groups
on one item. All three health status groups were significantly different regarding interest
in learning information about personal response to drugs and indicating interest in
learning risk for other disease/s. Two items not achieving statistically significant
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differences (see Table 5.4) had uniformly high levels of interest (89.5-99%). The value
of obtaining information about traits could not be assessed reliably because of missing
data (30.8% - 59.2%).
Six post-testing items inquired about genome results in relation to individual
health value. Results on Likert-type items (five scored 1-5, lowest for not at all or
strongly disagree; highest for extremely or strongly agree) identified value for all items
across all health status groups, and a pattern of highest to lowest scores from DI, to MM,
to H. Overall, means ranged from 3.46 (between neutral and somewhat agree) in the
Healthy group (for results helping to decrease risk of getting sick), to 4.16 in the DI
group for results being valuable. This latter item had uniformly high agreement across all
three groups (means 4.07 and 3.98 for MM and H, respectively). Statistically significant
differences were identified by t-tests on two items: 1) importance of information as
influencing future health management, between the DI and H groups (p = 0.019) and, 2)
ability to use the information to improve health (p < 0.001) between all groups.

Discussion
This large-scale study of self-initiated DTC genome testing users demonstrated
that categorizing individuals by health status based on both perceived health and
existence of a medical diagnosis created the four hypothesized groups, each having
clinically meaningful differences. This supported not only the previously established
influence of perceived health status related to existing medical conditions and
morbidity21,22, but contributed new awareness of its involvement in the health-related
choices of healthy persons.
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Health Status Groups
The groups were characterized to identify distinguishing characteristics and
answer the research questions. The Healthy group represents individuals who generally
do not come to the attention of the healthcare system, and the discrepant health status
groups were also of interest.
An unexpected finding was that there were only seven persons in the Health in
Question group. This group, who had no diagnosis but indicated their health as not good,
could represent the “worried well”19, persons lacking diagnosis for an existing health
problem, and/or be hoping for some type of specific information. The low number could
be explained if larger numbers exist but are subsumed into other groups, e.g., into the
MM or DI because they have a co-existing survey-specified diagnosis. This
consideration is supported by the 28 persons with diagnostic concerns identified through
analysis of text answers to reasons for pursuit of genome testing; however, none were in
the HQ group. Mitigating factors include limited query, attribution of concerns to others
(e.g., relatives, thus were not counted), not articulating this concern in their text answer,
or non-response. It could also be that an existing medical diagnosis was their highest
priority and/or that other concerns are addressed during regular healthcare visits.
Both the Diagnosed Ill and Medically Managed groups have medical diagnoses
yet sort into different groups, attesting to the influence of perceived health status.
Although group differences could be ascribed to differences in the mean number of
diagnoses for the DI and MM groups (4.40 versus 2.75, respectively), in both groups all
persons had medical diagnoses, the range in number of conditions was similar (nine
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versus ten, respectively) and their mean ages were similar. It is possible that the
nature/type of diagnoses differed between these groups, or that perceived risk contributed
to perceived health.

Perceived Risk
Risk Perception, a concept explored in prior DTC genetic testing studies as a
motivating factor or concern12,17,45, was examined in relationship to perceived health
status in the current study. Risk perception was found to be significantly different across
health status groups (see Table 5.3), being greatest in the DI group. From the distribution
of groups and conditions in Figure 5.1, it appears that both perceived health status and
medically defined health status contribute to risk perception. Two study findings suggest
that perceived health status may be an initial, greater and/or at least meaningful influence
for pursuit of genomic testing. The Healthy group, with perceived good health and no
medical diagnosis, had the lowest perceived risk. This makes sense and does not
necessarily imply the influence of perceived health status. However, the fact that the
MM group had a significantly lower perceived risk than the DI group supports the
potential influence of perceived health status (good in MM). The Health in Question
group, albeit small, were youngest (mean age 30.3) and were without a survey-specified
medical diagnosis, yet rated their health as fair or poor and had the highest mean (4.57)
for conditions at perceived increased risk. These persons were not identified by text
query of reasons for pursuit of genome testing, yet cursory examination of related text
fields identified statements such as: “…interested in Genomics, and think it is a good idea
given my medical history…” and “I chose … genetic testing because of some health
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issues I am experiencing”. Entries also included mention of desire for risk identification,
condition-specific or prevention-related information. A qualitative study involving this
HQ group and examination of all study population text answers may identify others in
this group, shed light on this perplexing issue and contribute to understanding health
factors relevant to effective and individualized healthcare.
Since the nature of the groups examined the combined effect of both health status
parameters, in relation to perceived risk, correlations were done to examine these
parameters separately. Perceived risk was weakly correlated (.272) with medical
diagnosis status alone, whereas perceived health status alone or combined with medical
diagnosis status demonstrated moderate correlations (.301 and .326, respectively). These
weak or moderate correlations are consistent with other findings. Of the persons (33)
indicating the highest number of conditions at increased risk (10-17), the majority (23)
had only one to three medical diagnoses. Of the persons (65) with the highest number of
medical diagnoses (7-10), only one indicated more than eight risk conditions. These
results support that perceived risk and perceived health status likely influence each other
(are positively correlated), yet also indicate that neither equates with nor substitutes for
the importance of integrating the other. Further studies may be helpful in clarifying risk
perception relevant to these health status groups, and perceived health status alone, such
as disorder-specific perceived liability/risk, positive family history and/or the results of
genomic testing.
Finally, it is noteworthy that regardless of health status group, the major targets of
perceived increased risk were heart disease, diabetes, skin cancer (melanoma), and breast
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and prostate cancer. These concerns may reflect positive family history, personal
experience, genome laboratory information, public education, the influence of mass
media, or interest in common diseases 11. This knowledge has relevance for clinicians,
researchers, personalized healthcare and genomic testing laboratories, relating to
readiness and timing of educational efforts, addressing screening and management of risk
factors, and discussion with potential pursuit of genomic testing.

Reasons for Pursuit of Genome Testing & Health Values
Across all three health status groups, at least 69% of participants assigned
importance to ten of twelve reasons for pursuit of genome testing (see Table 5.2); over
81% indicated the desire to improve health as important. The reasons posed to
participants for assessment of their interest were consistent with those identified in other
DTC genome testing studies, as was the finding that the majority assigned importance to
the desire to improve health 10,12,46. This response implies a perceived or expected
connection between genomic information and improving health. The lowest levels of
importance were associated with family members using personal genomics, and learning
about genetic make-up without physician involvement. The former suggests that family
pressures were not a major issue (although relevant for over half), and while the latter is
consistent with previous research demonstrating individual interest in collaborating with
healthcare providers11, 58-62% of participants rated this item as important. Possible
explanations include the inherent nature of persons who independently pursue genome
testing, public concerns about genetic discrimination (e.g., if genomic information gets
into their health records)47, or that genomic information is valued and cannot be obtained
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through their healthcare provider. Patients and providers could benefit from open
discussion to foster better understanding of health values, goals, concerns and utility of
genomic information toward personalized and more effective healthcare48.
The Diagnosed Ill and Medically Managed groups, despite having a medical
diagnosis and age in common, demonstrated statistically significant differences on four of
five reasons for pursuit of genome testing (see Table 5.2). These items related to
immediate medical risks (specific disease, drug response) or future planning (for self or
family). In contrast, the Medically Managed and Healthy groups both with perceived
good health, who were statistically different in age, income and diagnostic status, were
not significantly different on importance for three (of the five reasons) for pursuit of
testing. These reasons involved future plans, identifying disease risk and entertainment
value, suggesting less immediate perceived health needs.
The most dramatic finding was that all three groups were significantly different (p
< 0.001) on the two survey questions about importance of finding out about personal
response type to different medications (see Table 5.2 and Table 5.4). These results
demonstrate internal consistency, and also support potential clinical relevance for this
study’s health status categorization. The DI group had the highest percent interested in
drug response information, followed by the MM and then the Healthy group; however,
even that lowest encompassed 85.3%. The DI’s highest level of importance may be
because that they have the most to gain if genomic information helps in personalizing
more effective treatment or avoiding drug-related complications. This reasoning suggests
a greater influence of diagnostic health status, as opposed to perceived health, for

135

individual importance of learning their drug response type; however, this would not
explain why the MM group had a lesser percentage than the DI. These results, and the
lower percent of importance for the H group, support the influence of both medical
diagnosis and perceived health. This assessment is also supported by the significant
difference (p < 0.001) across all three groups for interest in learning about the risk for
other diseases. Overall, these findings demonstrate the personal value and importance
that individuals place on personalized drug-related information17, providing an insight
relevant to healthcare providers, policy developers and genome testing laboratories.
The Diagnosed Ill group also assigned the highest importance to receiving
information about personal risk for a specific disease, and creating a better plan for the
future (see Table 5.2). The desire for genomic information about an existing disease may
be surprising, yet is supported by another study49, although the reasons are not clear. Do
these people hope that genomic information will clarify or assign cause for their
condition, foster targeted treatment to ameliorate disease, and/or have prognostic value?
Or does this simply reflect a fundamental desire of people to value “answers”. These
potential reasons could interrelate with importance of creating a better plan for the future.
The DI group (e.g., if facing mortality) may view genomic information as important to
family, consistent with their assigned importance to genomic information for their
children (82.4%).
Finally, the MM and H groups also had a high percent assigning importance to
personal risk for disease (see Table 5.2). Participants across all groups indicated creating
a better plan for the future as important, yet the reasoning, values or goals behind those
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similar choices may be very different. This information may be useful to clinicians. For
example, for the DI group, planning for the future may warrant discussion of DNA
banking, whereas, for the perceived healthy groups, there may be a desire for early risk
identification, maintaining and promoting health, the issue of personal utility or value,
potential for motivating health behaviors, and/or implementing prevention measures.
Values Pre-testing: Although there was no specific health values question, ten
values-related items allowed some capture of this concept with inferences (see Table 5.4).
Interestingly, the nature of these value results paralleled the group findings for reasons
for pursuit of genome testing. In four out of five items, the DI group was significantly
different from the others. The one exception was the Healthy group for value (higher) of
carrier status information, possibly due to the questionnaire’s parenthetical reference to
pre-pregnancy planning and the group’s significantly younger (<0.001) mean age. Both
the Healthy and Medically Managed groups were similar (within 1.2% of each other) and
had lower frequencies (yet were 79.5–83.6%) than the Diagnosed Ill group for
considering how well results predict disease and agreement that what they (will) learn
from genome testing can help reduce the risk of getting sick. This again seemed to depict
a tendency for the DI group to be interested in their disease state, treatment and avoiding
illness.
Post-testing: The direct question of whether genome testing was valuable scored
highest across all groups, with no statistically significant difference. All groups also
indicated all values-related items as important; however, groups demonstrated
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statistically significant differences by t-tests involving genomic information as
influencing future health management and using it to improve health.
In summary, the study findings support personal health values as relevant to
pursuers of genome testing, and genomic information as having personal health value.
Despite this uniformity, the distinctive health status groups created in this study allowed
identification of statistically significant differences on noted values items based on
perceived health status (where groups with medical diagnoses differed). Although results
indicate genomic results have value, without further qualitative study, there is no way to
confirm assumed meaning or associated personal translation into health actions.

Study Issues and Limitations
The two surveys used for this study were based on validated instruments and
measures with demonstrated reliability, yet issues that limited results or interpretation
were the following: 1) the surveys were lengthy, potentially explaining the attrition
between the first and second surveys; 2) perceived redundancy or complexity in certain
sections, e.g., the second set of twelve risk related conditions with a less than 40%
response rate; however, it was apparent that some participants neglected to answer items
when their perceived risk was not increased; 3) potential overlapping answer options,
e.g., as encountered by persons without children, when offered both not applicable and
not interested regarding interest in testing for children; 4) confusing terminology or
phraseology—either technical, colloquial or with more than one possible interpretation,
e.g., “genomic information can help reduce the risk of getting sick” and “learning about
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‘traits’”; and, 5) interpretation of multiple choice or text answers by limited analysis or
assumed meaning, i.e., curiosity had different meanings.
Study specific issues arose. Both surveys included questions relevant to
examining this study’s subjective concepts (i.e., perceived health status, risk perception
and health values); however, these items were not repeated thus precluding pre- and posttesting comparison. The study design did not have a control population; all study
participants had pursued genome testing. Data analysis was limited in that most variables
were categorical and postulated to be in an interdependent relationship (as opposed to
independent/dependent). Health status groups, created by dichotomizing perceived
health status and existence of a medical diagnosis, may have restricted numbers in the
Health in Question group (that was too small to include in analysis).
Despite these considerations, the unique nature of this naturally occurring
population of persons who independently pursued genome testing, without involvement
of their healthcare providers or researchers, allowed examination of subjective healthrelated factors as potential influences on self-initiated individual health actions (i.e., DTC
genome testing).

Conclusions
Perceived health, alone or in combination with medical diagnostic status, is able
to distinguish or is correlated with overall personal health status, risk perception and
health values. This knowledge may facilitate integration of individual health perception
and health values into healthcare in order to collaboratively assess, prioritize and provide
personalized, efficient and cost-effective healthcare services. This approach is
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compatible with the Health Capability framework (basis for this study) and other
healthcare models that recognize individual health values, ability for personal choices and
responsible support of independent consumer actions including genomic testing on behalf
of their health needs and goals.
Existing perceived health status research is primarily structured from an illness or
biomedical framework, with outcomes measures such as delay in mortality, reduced
morbidity, improved functional status or cost/benefit ratios. Little research exists
involving healthy persons (except as controls) who seek health promotion
services21,22,50,51. These persons may be viewed as the worried well and/or as draining
limited healthcare resources19. On the other hand, consistent with public education
efforts promoting healthy behaviors, the value of screening and recognizing risk factors,
these people may represent persons interested in maintaining and promoting health and/or
having legitimate health problems that do not meet diagnostic criteria.
Perceived heath status is integral to overall health status. It may differentially
influence healthy persons, as opposed to persons as they age or health declines when
biomedical status may become more urgent and motivate action. This reasoning could
also support health-related actions of relatively healthy persons as they face acute illness
or anticipated health risk. This study population included 20% healthy persons, most of
who would not otherwise have come to the attention of the healthcare system. What
motivates these persons, as well as the other 80% with medical diagnoses, was explored
in the context of personal health perception, values and self-initiated health action vis-àvis genomic testing in hopes of informing gaps in the current healthcare system.
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Perchance we are not seeing some worthwhile outcomes (e.g., health behavior change)
because we are focused on the quantitative outcomes (delay of mortality, lesser morbidity
or measurable functional status) rather than the goals and values of the individuals and
the behaviors they deem worthwhile. Perhaps we could get better outcomes by
measuring an individual’s valued outcomes, and at the same time make more efficient use
of human and economic healthcare resources52.
Despite study limitations, genomic information is supported as both an individual
health value and as having perceived value for improved individual perspective on
personal health status, perceived control of health, ability to decrease the risk of getting
sick and the ability to improve health and influence future health management. Research
attests to the fact that users of DTC genome testing desire to discuss and share test results
with their healthcare providers11,17. So why do we not take advantage of this interest to
work collaboratively in partnership with our patients and the healthy public in decisions
about genome testing? Why do we indirectly support and promote individual
independent pursuit of this testing?
The underlying message of this study’s findings is that practitioners and patients
could likely benefit from integrating three simple questions into routine clinical practice.
These questions are the following: 1) “In general, how would you rate your health?”
Then ask, “Why?” 2) “What is your greatest health concern, need or value?” And, 3)
“What is your health goal?” From this, the practitioner can collaboratively determine an
effective and practical plan. As far as genomics, that would be the next question, as
genomic screening for risk becomes part of routine healthcare practices. Personalized
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healthcare integrating genome testing for everyone is on the horizon whether that is via
the DTC route, an indirect path or new approaches in conjunction with healthcare
providers.

References
1.

Wojcicki. A. INSIDE 23ANDME FOUNDER ANNE WOJCICKI'S $99 DNA
REVOLUTION. In: Murphy E, ed. FC online_Technology: Fast Company; 2013.

2.

Genetics & Public Policy Center. GPPC releases updated list of DTC genetic testing
companies. 2011;
http://www.dnapolicy.org/news.release.php?action=detail&pressrelease_id=145.
Accessed 31 August 2013.

3.

Gutierrez, A. FDA Close Out Letter 3:25:14 to 23andMe, Inc. Re: Adequate
response to Personal Genome Service warning. In: Services HaH, ed. Silver Spring,
MD: Health and Human Services, Center for Devices and Radiological Health,
Food and Drug Administration 2014.

4.

Clarke, T. FDA warns Google-backed 23andMe to halt sales of genetic tests.
Reuters. Nov 25, 2013, 2013.

5.

National Human Genome Research Institute. FDA Plans to Regulate LDTs. In:
Institute NHGR, ed2014.

6.

Evans, J. P., Khoury, M. J. The arrival of genomic medicine to the clinic is only the
beginning of the journey. Genetics in Medicine. 2013(Jan 10 (online)):1-2.

7.

Manolio, T. A., Chisholm, R. L., Ozenberger, B., et al. Implementing genomic
medicine in the clinic: The future is here. Genet Med. Jan 10 2013.

8.

Savage, S. K., Ziniel, S. I., Stoler, J., Margulies, D. M., Holm, I. A., Brownstein, C.
A. An assessment of clinician and researcher needs for support in the era of
genomic medicine. Personalized Medicine. 2014;11(6):569-579.

9.

Bloss, C. S., Darst, B. F., Topol, E. J., Schork, N. J. Direct-to-consumer
personalized genomic testing. Hum Mol Genet. Oct. 15, 2011;20(R2):R132-141.

10. Facio, F. M., Brooks, S., Loewenstein, J., Green, S., Biesecker, L. G., Biesecker, B.
B. Motivators for participation in a whole-genome sequencing study: Implications
for translational genomics research. European Journal of Human Genetics: EJHG.
Dec 2011;19(12):1213-1217.

142

11. Goldsmith, L., Jackson, L., O'Connor, A., Skirton, H. Direct-to-consumer genomic
testing: Systematic review of the literature on user perspectives. European Journal
of Human Genetics: EJHG. Aug 2012;20(8):811-816.
12. Gollust, S. E., Gordon, E. S., Zayac, C., et al. Motivations and perceptions of early
adopters of personalized genomics: Perspectives from research participants. Public
Health Genomics. 2011;15(1):22-30.
13. Su, Y., Howard, H. C., Borry, P. Users’ motivations to purchase direct-to-consumer
genome-wide testing: An exploratory study of personal stories. J Community
Genet. 2011;2(3):135-146.
14. Bloss, C. S., Ornowski, L., Silver, E., et al. Consumer perceptions of direct-toconsumer personalized genomic risk assessments. Genet Med. Sep 2010;12(9):556566.
15. McBride, C. M., Alford, S. H., Reid, R. J., Larson, E. B., Baxevanis, A. D., Brody,
L. C. Characteristics of users of online personalized genomic risk assessments:
Implications for physician-patient interactions. Genet Med. Aug 2009;11(8):582587.
16. McGuire, A. L., Diaz, C. M., Wang, T., Hilsenbeck, S. G. Social Networkers'
Attitudes Toward Direct-to-Consumer Personal Genome Testing. The American
Journal of Bioethics. 2009;9(6-7):3-10.
17. Kaufman, D., Bollinger, J., Dvoskin, R., Scott, J. Risky business: Risk perception
and the use of medical services among customers of DTC personal genetic testing. J
Genet Couns. Jun 2012;21(3):413-422.
18. Rumsfeld, D. “We do not know what we do not know”.
http://www.brainyquote.com/quotes/authors/d/donald_rumsfeld.html.
19. Garfield, S. R. The Delivery of Medical Care. The Permanente Journal.
2006;10(2):46-56.
20. Grosse, S. D., McBride, C. M., Evans, J. P., Khoury, M. J. Personal utility and
genomic information: Look before you leap. Genetics in Medicine.
2009;11(8):575-576.
21. Benyamini, Y., Idler, E. L. Community studies reporting association between selfreported health and mortality: Additional studies, 1995-1998. Res Aging
1999;21:392-401.

143

22. Idler, E. L., Benyamini, Y. Self-Rated Health and Mortality: A Review of TwentySeven Community Studies. Journal of Health and Social Behavior.
1997;38(March):21-37.
23. Okosun, I. S., Choi, S., Matamoros, T., Dever, G. E. Obesity is associated with
reduced self-rated general health status: Evidence from a representative sample of
white, black, and Hispanic Americans. Preventive Medicine. May 2001;32(5):429436.
24. Shmueli, A. Subjective Health Status and Health Values in the General Population.
Medical Decision Making. 1999;19(2):122-127.
25. Kumpusalo, E., Pekkarinen, H., Neittaanmäki, L., Penttilä, I., Halonen, P.
Identification of health status dimensions in a working-age population. An
exploratory study. Med Care. 1992;30(5):392-399.
26. Fulford, K. W. The value of evidence and evidence of values: Bringing together
values-based and evidence-based practice in policy and service development in
mental health. Journal of Evaluation in Clinical Practice. Oct 2011;17(5):976-987.
27. Ruger, J. P. Health capability: Conceptualization and operationalization. American
Journal of Public Health. Jan 2010;100(1):41-49.
28. Carere, D. A., Couper, M. P., Crawford, S. D., et al. Design, methods, and
participant characteristics of the Impact of Personal Genomics (PGen) Study: A
prospective cohort study of direct-to-consumer personal genomic testing customers.
Genome Medicine. 2014 (in process).
29. Heshka, J. T., Palleschi, C., Howley, H., Wilson, B., Wells, P. S. A systematic
review of perceived risks, psychological and behavioral impacts of genetic testing.
Genet Med. Jan 2008;10(1):19-32.
30. James, K. M., Cowl, C. T., Tilburt, J. C., et al. Impact of direct-to-consumer
predictive genomic testing on risk perception and worry among patients receiving
routine care in a preventive health clinic. Mayo Clinic proceedings. Mayo Clinic.
Oct 2011;86(10):933-940.
31. Sjoberg, L. Factors in Risk Perception. Risk Analysis. 2000;20(1):1-11.
32. Acheson, L. S., Wang, C., Zyzanski, S. J., et al. Family history and perceptions
about risk and prevention for chronic diseases in primary care: a report from the
family healthware impact trial. Genet Med. Apr 2010;12(4):212-218.

144

33. Green, R., Roberts, S. The PGen Study. 2012;
http://www.genomes2people.org/pgen/. Accessed 12/14/14.
34. McBride, C. M., Wade, C. H., Kaphingst, K. A. .Consumers' views of direct-toconsumer genetic information.. Annual Review of Genomics and Human Genetics.
2010;11:427-446.
35. Wade, C. H., Shiloh, S., Woolford, S. W., et al. Modelling decisions to undergo
genetic testing for susceptibility to common health conditions: An ancillary study of
the Multiplex Initiative. Psychology & Health. 2012;27(4):430-444.
36. Roberts, J. Anticipating response to predictive genetic testing for Alzheimer's
disease: A survey of first-degree relatives. Gerontologist. 2000;40(1):43-52.
37. Roberts, J. S., Cupples, L. A., Relkin, N. R., Whitehouse, P. J., Green, R. C. Genetic
Risk Assessment for Adult Children of People With Alzheimer's Disease: The
Evaluation and Education for Alzheimer's Disease (REVEAL) Study. Journal of
Geriatric Psychiatry and Neurology. 2005;18(4):250-255.
38. National Institute for Health and Clinical Excellence. Common Mental Health
Disorders. Identification and Pathways to Care. National Collaborating Centre for
Mental Health (NICE). London2011:57.
39. Kaufman, D., Murphy, J., Scott, J., Hudson, K. Subjects matter: A survey of public
opinions about a large genetic cohort study. Genet Med. Nov 2008;10(11):831-839.
40. 23andMe. 23andMe. 2014; https://http://www.23andme.com. Accessed October
30, 2014.
41. Pathway Genomics. Pathway Genomics. 2014; https://http://www.pathway.com.
Accessed October 30, 2014.
42. Eng, K. Personal communication: Sample size. 2014.
43. Smith, M. S., Wallston, K. A. How to measure the value of health. Health
Education Research: Theory and Practice. 1992;7(1):129-135.
44. Rokeach, M. The Nature of Human Values. New York: The Free Press; 1973.
45. Orom, H., Kiviniemi, M. T., Shavers, V. L., Ross, L., Underwood, W., 3rd.
Perceived risk for breast cancer and its relationship to mammography in Blacks,
Hispanics, and Whites. Journal of Behavioral Medicine. Jul 8, 2012.

145

46. Cherkas, L. F., Harris, J. M., Levinson, E., Spector, T. D., Prainsack, B. A Survey
of UK Public Interest in Internet-Based Personal Genome Testing. PloS one. 2010;5
10 | e13473(10):1-6.
47. Bunnik, E. M., Schermer, M. H., Janssens, A. C. Personal genome testing: Test
characteristics to clarify the discourse on ethical, legal and societal issues. BMC
Medical Ethics. 2011;12:11.
48. Camporesi, S. Better, and 'healthier' decision making through information
technology: Conference report from the Health 2.0 conference in San Francisco,
September 2011. Ecancermedicalscience. 2011;5:242.
49. Meisel, S., Wardle, J., Mountain, J. L., et al. Disease Status and Genetic Testing
Among Consumers of Two Personal Genomics Companies: Findings from the PGen
Study. American Society of Human Genetics; 10/25/13, 2013; Boston, MA.
50. Kulik, J. A., Mahler, H. I. M. Health Status, Perceptions of Risk, and Prevention
Interest for Health and Nonhealth Problems. Health Psychology. 1987;5(1):15-27.
51. Kolor, K., Duquette, D., Zlot, A., et al. Public awareness and use of direct-toconsumer personal genomic tests from four state population-based surveys, and
implications for clinical and public health practice. Genet Med. Oct
2012;14(10):860-867.
52. Sturmberg, J. P., O'Halloran, D. M., Martin, C. M. Understanding health system
reform--A complex adaptive systems perspective. Journal of Evaluation in Clinical
Practice. Feb 2012;18(1):202-208.

146

CHAPTER VI
EXTENDING THE HEALTH CAPABILITY CONCEPTUAL FRAMEWORK:
INDIVIDUAL PERCEIVED HEALTH STATUS AND HEALTH VALUES

Introduction
The main research question addressed the motivations for individual independent
pursuit of genome testing. The hypotheses tested whether individual perceived health
status (including perceived risk) and personal health values were influencing factors.
Chapter II provided the literature review and discussion of these concepts. Health
Capability, the conceptual framework, provided the basis for the proposed concept
mapping and relationships. The rationale and relevance of this model for this research
was presented in Chapter III. The major tenets of this framework included individual
health values, goals and health agency (supporting individual choice), the existence of
internal and external influencing factors consistent with research concepts and variables,
and its adaptability for extension to prevention and health promotion for DTC genome
testing. Perceived health status, the key concept/construct for this research, was
addressed in Chapter IV in a systematic review of the literature. Also included in this
literature review was a discussion of instruments and approaches used to capture and
measure this concept/construct. Chapter V presented the research study, methodology,
results and discussion, limitations and identified areas of need for future research and
clinical applications.
Chapter VI will present the impact of the study findings related to research
hypotheses and enhancing and modifying the proposed Health Capability concept
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mapping. Plans for additional research to clarify and characterize components of
perceived health status will also be presented. Finally, based on the outcomes of this
study, the need for future research will be presented.

Background
This dissertation research study examined health status, dichotomized by
perceived health status and a biomedical view of health status (existence of a medical
diagnosis), in DTC genome testing users. The primary hypothesis was that discrepancies
exist between the individual and biomedical view of health status. This hypothesis was
supported by the results of categorizing participants into health status groups that
confirmed the existence of the proposed four mutually exclusive health status groups.
These groups included the two discrepant groups, specifically persons with one or more
medical diagnoses who rated their health as good to excellent, and healthy persons who
rated their health as poor or fair. This latter group supported existence of the “worried
well” (Garfield, 2006). A healthy group was also identified, as persons without a medical
diagnosis and rating their self-health as good to excellent. Each of these groups raises
questions as to differences in the reasons (motivations) for pursuit of genome testing,
health values and distinguishing characteristics. Findings also have relevance for
prioritization in clinical practice, individual health behaviors, cost-effective healthcare
services and research.
The Health Capability model (Ruger, 2010) was used as the conceptual
framework for this study. This is a relatively young paradigm without an operational
model or measurement instrument and little applied clinical research. The unique
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contribution and potential for the Health Capability framework is its commitment to
individual health values, support for individual health goal achievement, research at the
individual level with extension from there to the population level, and its adaptability for
application to prevention and independent individual action in pursuit of heath goals (i.e.,
genome testing).

Health Capability: Proposed Concept Mapping—Revised
In Chapter II, concept mapping was proposed to operationalize Health Capability
(Ruger, 2010) for this study and evaluate its use for this dissertation research. It was also
intended that this model be applicable to other potential clinical and research use in the
context of a theoretical framework committed to physician (practitioner)—patient
(individual) partnership, recognition of individual health values and goals, and support
for prevention at the individual as well as public health levels. The original concept
mapping has been updated and revised based on the results of the dissertation research
(see Figure 6.1, including Pearson correlation values and highlighting of study concepts
as discussed below). Although the research hypotheses did not include one specific to
Health Capability, the fact that this model served as the framework for study concepts,
for proposed and tested relationships, and for adaptation for prevention and health
promotion vis-à-vis DTC genome testing, coupled with the study findings (presented in
Chapter Five and discussed further in this chapter), is consistent with initial assessment
and support for its use and further study in DTC genome testing research.
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Health Status
This concept previously included “health functioning” in its title since both terms
were included in the Health Capability profile (Ruger, 2010). However, health
functioning reflects only limited measures of health status, usually in relation to disability
or the ability to perform activities of daily living (Lachman & Agrigoroaei, 2010;
Schiffman, Jacobsen, & Whitcup, 2001). Thus, Health Status (green highlight) was
modified to encompass three measures of health (see Figure 6.1): the two components
(blue highlight) specified in the Health Capability profile (Ruger, 2010), plus the addition
of perceived health status (yellow highlight).

1. Functional: Maintained as a component of health status, including its
measurement (e.g., by the SF-36 (Ware, 2009; Ware & Sherbourne, 1992).
2. Health Conditions and Risks (objective): Maintained as a component of
health status, including its measures (e.g., vital signs, EKG, CBC, screening,
etc.). The term objective is included in order to distinguish this from the
individual (subjective, perceived health) component. The Pearson correlation
coefficient (.272), based on results of this research, has been added to the
relationship line between Health Status (the construct, represented by the
research Health Status groups) and the biomedical measure of health status
(existence of a medical diagnosis). Although the correlation analysis was
found to be statistically significant, the large study population (N = 1455) may
have contributed to inflating its apparent impact since the correlation value
itself (.272) is considered only weakly positive.
3. Individual Perceived Health (subjective): This component was added as part
of the proposed concept mapping prior to the completion of the dissertation
research. It is consistent with Health Capability’s philosophical recognition of
an individual’s view and values for their health, as well as its respect for an
individual’s view and values for their health, as well as its respect for an
individual’s assessment of their health as evidenced by inclusion of measures
of self-reported health functioning. However, measures of functional health
status and biomedical health status cannot capture the totality of an
individual’s perceived health, what is of personal relevance and value, and
what impacts actions and outcomes. Studies of individual perceived health
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have demonstrated its significant and unique contributions in outcome studies
of mortality and morbidity (Benyamini & Idler, 1999; Idler & Benyamini,
1997). However, there is little research from a prevention focus, and the
limited research that exists is population and disease/illness oriented (Chern,
Wan, & Pyles, 2000). This was discussed in the review of literature in
Chapter Four. Assessment of health status from the individual perspective,
and awareness of personal health values, has been recommended as an integral
component for routine healthcare practice essential to the ability to evaluate
meaningful outcomes (Barr, 1995). Thus, based on the literature review,
previous studies and the current study results that support the distinct nature of
individual perceived health status (yellow), and its association with the overall
construct of Health Status (green), the relationship line between them was
changed to solid (from dashed) and the relevant correlation values were
added.

Perceived Health Status (Hypothesis 1)
Perceived health status, the subject of literature review as presented and discussed
in Chapter IV, was captured, measured and validated in research either by a single Likerttype item or a measurement instrument (Benyamini & Idler, 1999; Idler & Benyamini,
1997; Leung, Luo, So, & Quan, 2007). An instrument to assess perceived and targeted
health status is frequently used in studies involving disease, mortality, morbidity,
disability or interventions (Bardsley, Astell, McCallum, & Home, 1993; Salaffi, Stancati,
& Carotti, 2002). The single item is preferred for brevity and where an overall
perspective of perceived health status will achieve the study’s need or intent. Based on
the PGen survey and database, perceived health was represented by a single item in the
dissertation research. It was used to create Health Status groups combining both the
subjective individual perception of health with an objective biomedical perspective of
health (existence of medical diagnosis). Hypothesis 1, that discrepancies existed between
these two perspectives, was confirmed by identification of participants within all four
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health status categories. This result supported the integration of perceived health status
as a separate, contributory subdomain of Health Status.

Perceived Health Status: Proposed Components
Perceived health status was proposed to be comprised of seven subdomains
(components; see Figure 6.1) based on existing genetics, genomics and perceived risk
research and literature (Cameron, Sherman, Marteau, & Brown, 2009; Carere et al., in
press; R. Green & Roberts, 2012b; Heshka et al., 2008; D. J. Kaufman et al., 2012; Orom
et al., 2012; Valdez, Yoon, Qureshi, Green, & Khoury, 2010). The subdomain of primary
focus, in conjunction with the examination of individual health status and personal health
values, was perceived risk. This component is discussed below, as are variables relating
to limited components of other perceived health status subdomains, together with the
implications based on the study findings. These subdomains are:

1. Physical Factors: Discussed below
2. Mental/Psychological Factors: Relate to mental, emotional or psychological
health status, including any existing medical condition that the individual
views as compromising to his/her health
3. Familial Factors: Relates to health or risk status based on ancestry, ethnicity,
race, condition or potential medical problem that the individual views as
impacting (or potentially) his/her health risk (e.g., a condition that tends to run
in the family)
4. Genetic Factors: Relates to existence (per individual report) of a known
specific genetic disease, mutation, or genomic risk associated with a mutation
in oneself or one’s relative
5. Environmental Factors: Includes exogenous risk factors over which the
individual has little or no personal control, such as those existing in one’s
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place of employment, geographic area, and/or as reportedly prescribed or
medically necessary (e.g., per one’s healthcare provider)
6. Lifestyle Factors: Includes behavioral factors over which the individual has
personal control, such as smoking, alcohol consumption, use of illegal, nonprescription or self-initiated drugs (e.g., not prescribed by one’s healthcare
provider)
7. Perceived Risk Factors: Discussed below

Physical factors: In the proposed concept mapping, physical factors related to
physical health status, including any existing medical condition that the individual
viewed as impacting or compromising to his/her health. This subdomain is incorporated
in all three measures of health status (functional, biomedical and perceived). The focus
discussed here is limited to assessments and comments in the context of perceived health
status. Physical health is known to impact one’s perceived health, yet physical health
status is also related to biomedical health and existing diagnosis, and functional health
status, both of which also contribute to quality of life considerations (Lachman &
Agrigoroaei, 2010). This study was limited to the examination of biomedical health
captured as the existence (or not) of one or more medical diagnoses, and was compared
with and noted to have distinctions from, an individual’s perceived health status. To
what extent perception of physical health status contributed to one’s overall perceived
personal health status is not known and could not be characterized/quantified by this
study. However, given the finding that the health status groups with medical diagnoses
had significantly different (higher) perceived risks (number of conditions at increased
risk), and that previous research supported the importance of functional health (Haseen,
Adhikari, & Soonthorndhada, 2010; Lachman & Agrigoroaei, 2010), it may be that
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perceived physical health is more relevant when it is perceived as compromised or urgent
(as opposed to when one is healthy) (Mann, de Ridder, & Fujita, 2013). In this
dissertation, related to Hypothesis 3, age was examined in association with health status
groups, and separately, with individual perceived health status. Statistically significant
differences between health status groups supported rejection of the null Hypothesis 3 that
there would be no difference. However, significant differences were limited to
combinations with the Healthy group, whose mean age was 37.5, in contrast to 51.2 and
50.1 in the Diagnosed Ill and Medically Managed groups, respectively. These results are
consistent with other studies that demonstrate conflicting results related to age and
pursuit of DTC genome testing (Bloss et al., 2010; Cherkas et al., 2010). It is also
noteworthy that in the overall study population, individual age was not correlated with
perceived health status. This latter finding lent support to the position that physical
health status may be sufficiently addressed by the combination of functional and
biomedical health status measures. Further, if one’s physical health is not compromised
or of concern, it may be that its influence or contribution to perceived health status
essentially becomes negligible. This would be relevant for future research to understand
individual motivations for health actions.
Perceived Risk (Hypothesis 4): Based on the previous literature review and
studies incorporating perceived risk (or perception of risk) related to genomics (Acheson
et al., 2010; Heshka et al., 2008; D. J. Kaufman et al., 2012; McBride et al., 2009;
Sjoberg, 2000; Tarr et al., 2014) performed to develop Health Capability, the concept was
defined as individual recognition or appreciation of real or believed vulnerability,
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compromised health status and/or likelihood of a disease(s), disorder(s) or condition(s)
(specific or in general), as either increased relative to others, or existing to an extent
beyond that acceptable to that individual. This definition reflects the individual’s
subjective perspective and values, consistent with Health Capability and the nature of
survey data used in this dissertation research. Perceived risk was represented in the
dissertation on an individual level as the sum of perceived risks (likelihood to develop)
for twenty-four survey-specified conditions. Rejection of the null Hypothesis 4 that
projected no significant difference between health status groups was supported by the
finding of significant differences between health status groups by t-tests. Separate
correlation analyses of perceived risk identified the highest correlation (.326) with
perceived health status, the lowest (.272) with biomedical health status, and a middle
value (.301) with the combined health status groups. These results supported a
relationship between perceived risk and individual health status, both from objective
criteria and subjective individual perspectives, warranting inclusion of both as relevant to
individual health status and assessment.
Research studies have examined and confirmed perceived risk as an interest,
reason or motivator for individual pursuit of DTC genetic or genomic testing (Goldsmith
et al., 2012; Gollust et al., 2011; David Kaufman, Bollinger, Devaney, & Scott, 2010).
Another study determined that persons who pursued DTC genome testing were most
interested in the condition or diagnosis they had (Meisel et al., 2013). However,
perceived risk has not been studied as to its relative contribution among other personal
(subjective) motivators for pursuit of DTC genome testing, or as to its association with
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one’s combined perceived and medical diagnostic health status (as supported in the
current study). This study found perceived risk to be among the highest for the same
medical conditions (i.e., heart disease, diabetes, skin cancer, breast cancer, prostate
cancer, and high cholesterol), across all health status groups, ranging lowest in the
Healthy group, to intermediate in the Medically Managed group, to highest in the
Diagnosed Ill group. These conditions are consistent with risk concerns identified in
prior DTC genome testing studies [e.g., heart disease (Gollust et al., 2011)], and
accounted for risk concerns in a minimum of 13%, and a maximum of 48%, of persons
within the health status groups. Whether or not concern about a single condition, or a
collective sum of perceived risks, is a significant contributor to pursuit of DTC genome
testing remains uncertain. Furthermore, this issue raises the question of a threshold of
tolerance for risk or need for information, that influences health-related action (i.e., DTC
genome testing). Studies are needed to address these potential influences, as well as to
explore the possibility of triggering events, needs or perceptions.
An important realization that derived from this dissertation process and the
outcomes of the research related to perceived risk versus perceived health. It is
noteworthy that, with the exception of perceived risk, the sub-domains of individual
perceived health proposed in the concept mapping all related to both perceived health and
to perceived risk (components as identified by the literature review). However, since the
correlation between them is at most a moderate positive (.326), they are neither mutually
exclusive nor would these results suggest the use of one as more important or as a
surrogate for the other. This is an important finding relevant to appreciating the gaps and
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potential biases in the healthcare literature, research and clinical practice. A primarily
risk focus reflects a disease/illness model and minimization or lack of health related
freedoms and choices if one is deemed healthy (i.e., not sick) (Boenink & van der Burg,
2010). Perceived health is typically not the focus or included in research. If it is
included, it is generally disease focused or captured by a single question, reported as
general frequencies with little other application (Barr, 1995; Carere et al., in press;
Lichtenstein & Thomas 1987; Miilunpalo et al., 1997). Thus, not only does this indicate
a gap in research and understanding of the potential impact or influence of perceived
health status, but it also raises awareness and questions related to the evaluation of and
healthcare priorities for healthy, or seemingly healthy, persons. This includes the need
for further study of the “worried well”, and the extent of their numbers that may be
obscured within other health status categories or non-responses. It also includes the goals
and values of healthy persons, with the potential for adjusting healthcare priorities,
allocation and type of services, and contributing to resource-effective health promotion.
These issues were discussed in Chapter V.

Reasons for Pursuit of Genome Testing and
Socio-demographics (Hypotheses 2 & 3)
The reasons for pursuit of genome testing, associated with Hypothesis 2,
interrelate with health values as well as health goals, and are addressed in the Discussion
section. Socio-demographic characteristics, and support for or rejection of Hypothesis 3,
are considered as relevant in the following sections.
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Health Values (Hypothesis 5)
Health values, addressed in the review of literature included in Chapter II, were
operationalized in the dissertation research using PGen survey Likert-type questions
(from both the pre-testing and the two week post-testing surveys) relating to items of
individual health importance, interest, consideration and/or value. The study results
confirmed an association between Health Values and Health Status groups. Two of the
five health values items (importance of genome results for future health management, and
for health improvement) were significantly different by t-tests between health status
groups. This finding supports rejection of the null Hypothesis 5 that there would be no
difference in health value of genomic information between health status groups. The
results indicate that there is a distinctive contribution from (subjective) perceived health
as opposed to the (objective) existence of a medical diagnosis (i.e., if unsupported, all
persons with a medical diagnosis, or all persons with perceived good health, would not be
significantly different). On the other hand, the fact that all health status groups: 1) were
not significantly different on three of the five items; 2) all rated all items as having at
least some value/importance (means ranging from 3.46 to 4.16, with 3.0 being neutral
and 5.0 being strongly agree); and, 3) uniformly rated the highest for genome results as
being valuable to their health [consistent with previous research (McBride et al., 2009)],
supported the relevance of health values to pursuit of genome testing, and potentially to
other self-initiated health behaviors. The comparison of pre-testing expected health value
of genome test results with post-testing individual value based on actual results was not
possible since the same measures were not repeated. However, the findings do contribute

159

to supporting individual health values as a primary component of the proposed
operationalization of Health Capability, and its applicability to DTC genome testing
research.
Future study of the combined contributions and effects of individual perceived
health and health values on individual health goals and behaviors is supported by the
current results, as well as other research (Shmueli, 1999). A future study will examine an
individual’s perceived health status combined with health values (i.e., the items that
differentiated health status groups in the current study), in relation to an individual’s
intended behavior change as stated at two weeks post testing compared with their stated
health behaviors as reported at six months.

Study Limitations
One limitation of this study is that the correlation coefficient between overall
Health Status and Individual Perceived Health was based solely on the health status
groups for the former, and the limited measure of perceived risk for the latter. Despite
this limitation, a relationship was demonstrated (see Figure 6.1; the line between them
has been changed to solid & non-directional).
Limitations also exist related to the fact that this study involves secondary
analysis of data from the original PGen research surveys. Multiple-choice questions were
framed from, and/or provided answer options supported by, results of previous DTC
genome testing research studies; however, that approach did not allow for other possible
individual responses. Another limitation in the current study was the inability to evaluate
individual health values pre-testing since that concept and related questions were not
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included in the pre-testing survey. Despite these limitations, the PGen survey questions
and data did include questions in which relevant individual answers and qualitative data
could be captured. Targeted questions with text answers were queried for keywords that
confirmed, on a preliminary basis, the existence of different individual perspectives
related to reasons for testing and interpretation of terminology used (e.g., curiosity).
These subjective text answers coupled with the ability for a mixed qualitative and
quantitative approach to data analysis provided a unique dimension not included in
existing research (Bloss et al., 2010; Goldsmith et al., 2012).
Generalizability was also a relevant issue from two perspectives. The current
study population, participants in the PGen study, demonstrated socio-demographic
characteristics consistent with previous DTC genome testing users research (Bloss et al.,
2010; Goldsmith et al., 2012; McGuire et al., 2009). Thus, study results are likely
generalizable to other DTC genome testing users. On the other hand, this study
population, consistent with the previously cited studies, is different from, and is not
generalizable to, the general population. Specifically, these cited studies of DTC users
have found that participants tend to have higher levels of education; have higher incomes;
be Caucasian; be professionals, scientists, in academia or employed in mid to upper level
jobs; and indicate their perceived health as good. Importantly, however, as the cost of
DTC genome testing decreases, public awareness increases, marketing and new genome
related testing services are offered (e.g., prenatal sex typing), NIH funded research exists
for new approaches to early risk identification and/or health promotion using genomic
screening (e.g., in newborns), FDA regulatory authority has gaps in controls of DTC
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laboratory tests, and/or genome testing (or screening) further demonstrates clinical utility,
there could be a significant increase in the number of individuals pursuing genome
testing, as well as the socio-demographics of DTC testing users.

Discussion and Conclusions
Perceived health status of the DTC genome testing users in this study spanned all
five Likert-scale choices from excellent to poor, with the majority (1,235/1,455) rating
their health as good to excellent, regardless of medical diagnostic status. However, by
sorting the study population into four mutually exclusive health status groups based on
inclusion of perceived health status, distinguishing characteristics emerged. Persons with
a biomedical diagnosis and perceived poor or fair health expressed higher levels of
interest for genomic information of immediate personal relevance, or for their family, i.e.,
about their current medical condition, other health risks and response type to different
medications. In contrast, study respondents indicating their health as good to excellent,
whether or not they had a medical diagnosis, expressed greater interest in genomic
information related to future health, risks and ability for prevention (although also
interested in the previously noted health information). Thus, perceived health status was
associated with the type of genomic information sought, the percent indicating an item as
important, and interest in immediate versus future use.
Health values were supported as important to the DTC genome testing study
participants. All three health status groups assigned the highest scores to genomic
information as being valuable to health (see Figure 6.2). In addition, group means on all
other health values items were in the direction of having value, with some items
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Figure 6.2: Genome Test Results—Value To Respondents’ Health.

KEY: **Statistical significance. Set of bars at right is based on maximum of 3.

extending into the range of extremely important/valuable. Three observations are
noteworthy. The highest mean scores for all health values items occurred in the
Diagnosed Ill group. This finding suggests that persons with medical diagnoses and selfrated fair or poor health may perceive the greatest potential for genomic information to
offer some help for their current health. Second, all groups scored similarly (high)
related to genomic information as providing a better perspective on their health status and
for feeling like they had more control of their health. This supports that DTC genome
testing users tend to value an active role in health related decisions and ability to take
charge of their health. Third, all respondents indicated, in a positive direction, that
genomic information can be used to improve their health. Whether or not that is accurate
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in the context of clinical utility, it is seen as valuable for personal utility. This
information has direct relevance to healthcare providers, prioritization of services,
appreciation for what is meaningful to consumers, targeting health education (and needs)
and collaborative decision-making.
This study’s survey requested participants to indicate the importance of twelve
reasons for pursuit of DTC genome testing, based on motivations identified by previous
research as discussed in Chapter II. Some of these reasons overlap into the realm of
individual health values and health goals. For example, close to 100% of respondents in
all health status groups indicated that their pursuit of genome testing considered obtaining
(the goal of) personal health information (see Table 5.2, Chapter V). This goal is further
supported by the relatively high percent among all groups indicating the desire for
genomic information about their response type to medications.
The research Hypothesis 2 (null), stating that there would be no difference
between health status groups related to reasons for pursuit for genome testing, was
rejected for some reasons (e.g., finding out response type to different medications) and
was supported for others (e.g., curiosity, and family members using personal genomics).
An important consideration, however, is that on several reasons for pursuit of genome
testing (e.g., genomic information related to personal risk for disease, for future children
and the desire to improve health) over two-thirds of persons in all groups scored the
reasons as of interest. These findings not only indicate an explanation for apparent nonsignificant differences between groups (since the majority in all groups were interested),
but suggest that DTC genome testing users are interested in goals associated with
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prevention and health promotion. It is also relevant to note that although more than 90%
in each group responded that curiosity was involved, with that reason potentially viewed
as having no clinically relevant health value or goal (and similar regarding pursuit of
testing as fun and entertaining), an initial review of text answers of reasons for pursuit of
genome testing attributed very different uses or meanings to curiosity. This study finding
highlights a dimension important to clinicians and researchers concerning the structure,
content and selection of survey questions, but also their interpretations.
The results of this study demonstrated that perceived health status distinguished
health status groups and made a significant difference in individual reasons for seeking
DTC genome testing, goals for genomic information and in risk perception. Perceived
health status served as a complement to, and at times evidenced a higher correlation, than
biomedical health status (e.g., for perceived risk status). The importance of individual
health values was also demonstrated in self-initiated genome testing users. These
findings lend support for use and testing of the Health Capability conceptual framework
as a model for integrating individual health values and goals into healthcare services,
delivery and policy directions. This study’s results contribute to furthering understanding
of the influence of perceived health status and its potential for application in the context
of early identification of risk, prevention and health promotion. The modified concept
mapping provides a basis for further study of individually relevant health concepts and
factors that may influence health behaviors, such as self-initiated health action (e.g., DTC
genome testing, or exercise program). It also facilitates the ability to test for existence of
triggers, a threshold effect, or factors impacting readiness for health information and
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commitment to healthy behaviors. This knowledge has the potential for more effective
strategies for provision of healthcare and use of its limited resources.

Future Research
The findings of this study indicate the need for research in three areas. First, there
is a need for research and strategies spanning beyond traditional models of healthcare to
incorporate prevention, as well as integrating subjective individual perceived health,
personal health values and goals, and motivating factors impacting adherence to health
behaviors (Breckenridge & Eichler, 2013; Mann et al., 2013; Ruger, 2010). This requires
a theoretical or conceptual healthcare framework, such as Health Capability, that
philosophically and practically integrates these principles. The model requires a systems
perspective, yet commitment to the individual, to facilitate and recognize contributions
and perspectives from all stakeholders while respecting cost-effective and health
promotion oriented healthcare (J. P. Sturmberg et al., 2012).
Second, based on the established ability to represent, measure and integrate
perceived health status by a single Likert-type subjective item, it is reasonable to consider
the possibility of a similar approach for perceived risk. Although typically perceived risk
is posed in the context of specific disease or risks, one or two overall measures of
perceived risk may serve as an effective screening or triaging measure. For example,
asking the patient/respondent what, in general, they consider their level of health risk to
be as compared to others of similar age and sex, akin to previously posed survey
questions (R. Green & Roberts, 2012a; D. J. Kaufman et al., 2012). Secondly, a question
needs to be posed for the individual to consider the condition for which they feel they are
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at greatest risk, then rating that by a Likert-type item or numeric measure. Working from
the focus of this dissertation, the next step would be to combine these two (or three)
values to represent perceived health status. In combination with, and contrast to medical
health status, these groups and variables could be examined related to the potential
impact on self-initiated health action and behavior. This approach has two immediately
relevant benefits. Clinically, there is the potential to efficiently identify the existence of
some condition of high-risk concern to the individual, with the possibility to intervene in
a more timely and effective manner. From a research context, this approach may provide
a method to test and compare the separate contributions of other subjective personal
health/risk factors versus a combined measure.
Third, in addition to the constructs, concepts and relationships proposed,
examined and modified, there remains an over-riding question relevant to healthy
persons, whether they are persons without a medical diagnosis or they are persons with a
medical diagnosis but with perceived good to excellent health. That question is “Why
now?” Why have these persons, spanning significantly different ages, diagnostic status
and income levels chosen to pursue self-initiated genome testing when they did? This
author is proposing, and adding to the concept mapping, a “triggering” event (or
threshold effect). This would be something subjective, beyond the combined interaction
of medical health status, perceived health status, and individual health values and goals—
that provides the impetus for action in healthy persons, or apparently non-acute or not
medically necessitated situations. This dimension of perceived health status is the
intended direction of future research. These events are proposed to include factors such
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as the individual’s age (e.g., being the same age as the parent when diagnosed), exposure
to a perceived health risk (e.g., with potential concern for cancer), change in health status
(i.e., newly diagnosed medical condition), and other personal factors of which we likely
do not know what we do not know (Costello, 2014). In addition, concepts from other
disciplines may be relevant to incorporate into an interdisciplinary approach to research,
such as self-regulation and self-realization (Mann et al., 2013; Miquelon & Vallerand,
2008), in the context of motivating factors for self-initiated pursuit of health-related
information, as with genome testing.
Further research is also planned to examine the other proposed subdomains
(components) of perceived health (and/or risk), their association with and potential
contribution to differentially influencing perceived health status, and if/how these factors
are individually prioritized related to health values. These issues have relevance to
individualizing, prioritizing and effecting quality and cost-effective healthcare services
and policy, collaborating with consumers, and promoting health at individual and public
health level.
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